

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Tolerability of bedtime diuretics: A prospective cohort analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-068188
Article Type:	Original research
Date Submitted by the Author:	14-Sep-2022
Complete List of Authors:	Garrison, Scott; University of Alberta Faculty of Medicine & Dentistry, Family Medicine Kelmer, Michael; University of Alberta, Faculty of Nursing Korownyk, Tina ; University of Alberta Faculty of Medicine & Dentistry, Family Medicine Kolber, Michael; University of Alberta Faculty of Medicine & Dentistry, Family Medicine Allan, Gary; University of Alberta Faculty of Medicine & Dentistry, Family Medicine Bakal, Jeffrey; Alberta Health Services, Provincial Research Data Services Singer , Alexander; University of Manitoba, Family Medicine Katz, Alan; University of Manitoba, Community Health Sciences Mcalister, Finlay; University of Alberta Faculty of Medicine & Dentistry, Medicine Padwal, Raj S ; University of Alberta Faculty of Medicine & Dentistry, Medicine Lewanczuk, Richard; University of Alberta Faculty of Medicine & Dentistry, Medicine Hill, Michael; University of Calgary Cumming School of Medicine, Clinical Neurosciences McGrail, Kimberlyn; The University of British Columbia, School of Population and Public Health O'Neill, Braden; University of Toronto, Family and Community Medicine Greiver, Michelle; University of Toronto, Family and Community Medicine Manca, Donna; University of Alberta Faculty of Medicine & Dentistry, Family Medicine Mangin, Dee; McMaster University Faculty of Health Sciences, Family Medicine Wong, Sabrina T.; The University of British Columbia, School of Population and Public Health Kirkwood, Jessica; University of Alberta Faculty of Medicine & Dentistry, Family Medicine McCormack, James; The University of British Columbia, Faculty of Pharmaceutical Sciences Yeung, Jack; Alberta Health Services, Provincial Research Data Services Green, Lee ; University of Alberta Faculty of Medicine & Dentistry, Family Medicine
Keywords:	Hypertension < CARDIOLOGY, CLINICAL PHARMACOLOGY, PRIMARY CARE, Cardiology < INTERNAL MEDICINE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Tolerability of bedtime diuretics: A prospective cohort analysis

Scott R Garrison, Professor;^{1,2} Michael D Kelmer, student;^{1,2} Tina Korownyk, Professor;^{1,2} Michael R Kolber Professor;^{1,2} G Michael Allan, Professor;^{1,2} Jeffrey A Bakal, Program Director;³ Alexander G Singer, Associate Professor;⁴ Alan Katz, Professor;⁴ Finlay A McAlister, Professor;⁵ Raj S Padwal, Professor;⁵ Richard Lewanczuk, Professor;⁵ Michael D Hill, Professor;⁶ Kimberlyn McGrail, Professor;^{7,8} Braden G O'Neill, Assistant Professor;⁹ Michelle Greiver, Associate Professor;⁹ Donna P Manca, Professor;² Dee A Mangin, Professor;¹⁰ Sabrina T Wong, Professor;^{8,11} Jessica EM Kirkwood, Assistant Professor;^{1,2} James P McCormack, Professor;¹² Jack MS Yeung, Programmer;³ Lee A Green, Professor.^{1,2}

¹Pragmatic Trials Collaborative, University of Alberta, Edmonton, AB; ²Dept of Family Medicine, University of Alberta, Edmonton, AB; ³Provincial Research Data Services, Alberta Health Services, Edmonton, AB; ⁴Dept of Family Medicine, University of Manitoba, Winnipeg, MB; ⁵Dept of Medicine, University of Alberta, Edmonton, AB; ⁶Cumming School of Medicine, University of Calgary, Calgary, AB; ⁷School of Population and Public Health, University of Alberta, Edmonton, AB; ⁸Centre for Health Services and Policy research, Vancouver, BC; ⁹Dept of Family and Community Medicine, University of Toronto, Toronto, ON; ¹⁰McMaster University, Hamilton, ON; ¹¹School of Nursing, University of British Columbia, Vancouver, BC; ¹²Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC

Corresponding Author:

Scott R Garrison MD, PhD, CCFP; 6-60 University Terrace, University of Alberta, Edmonton, Alberta, Canada, T6G 2T4; Phone: 587-785-3012; Email: scott.garrison@ualberta.ca

Co-authors:

Michael Kelmer	kelmer@ualberta.ca	Braden O'Neill	braden.oneill@gmail.com
Tina Korownyk	cpoag@ualberta.ca	Michelle Greiver	Michelle.Greiver@nygh.on.ca
Michael Kolber	mkolber@ualberta.ca	Donna Manca	dpmanca@ualberta.ca
G Michael Allan	mgallan@ualberta.ca	Dee Mangin	mangind@mcmaster.ca
Jeffrey Bakal	jbakal@ualberta.ca	Sabrina Wong	sabrina.wong@ubc.ca
Alex Singer	alexandersinger@gmail.com	Jessica Kirkwood	jek5@ualberta.ca
Alan Katz	Alan_Katz@cpe.umanitoba.ca	James McCormack	james.mccormack@ubc.ca
Finlay McAlister	finlay.mcalister@ualberta.ca	Jack Yeung	ManShun.Yeung@albertahealthservices.ca
Raj Padwal	rpadwal@ualberta.ca	Lee Green	lagreen@ualberta.ca
Richard Lewanczuk	rlewancz@ualberta.ca		
Michael Hill	michael.hill@ucalgary.ca		
Kimberlyn McGrail	kim.mcgrail@ubc.ca		

ABSTRACT

OBJECTIVES

We sought to validate, or refute, the common belief that bedtime diuretics are poorly tolerated due to nocturia.

DESIGN

Prespecified prospective cohort analysis embedded within the randomized BedMed trial, in which hypertensive participants are randomized to morning vs. bedtime antihypertensive administration.

SETTING

352 community family practices across 4 Canadian provinces between March 2017 and September 2020.

PARTICIPANTS

552 hypertensive patients (65.6 years old, 57.4% female) already established on a single once-daily morning antihypertensive and randomized to switch that antihypertensive to bedtime. Of these, 203 used diuretics (27.1% thiazide alone, 70.0% thiazide/non-diuretic combinations) and 349 used non-diuretics.

INTERVENTION

Switching the established antihypertensive from morning to bedtime, and comparing the experience of diuretic and non-diuretic users.

PRIMARY AND SECONDARY OUTCOME MEASURES

PRIMARY OUTCOME: Adherence to bedtime allocation time at 6-months (defined as the willingness to continue with bedtime use, not an assessment of missed doses). SECONDARY 6-

1
2
3 MONTH OUTCOMES: 1) Nocturia considered to be a major burden, 2) Increase in overnight
4 urinations/week. All outcomes were self-reported, and additionally collected at 6-weeks.
5
6

7 8 **RESULTS** 9

10 At 6-months: Adherence to bedtime allocation time was lower in diuretic users than non-
11 diuretic users [77.3% vs 89.8%; difference 12.6%; 95%CI 5.8% to 19.8%; $p < 0.0001$; NNH 8.0],
12 and more diuretic users considered nocturia a major burden [15.6% vs 1.3%; difference 14.2%;
13 95%CI 8.9% to 20.6%; $p < 0.0001$; NNH 7.0]. Compared to baseline, diuretic users experienced
14
15 1.0 more overnight urinations/week [95%CI 0.0 to 1.75; $p = 0.01$]. Results did not differ
16
17 between sexes.
18
19
20
21
22
23
24

25 **CONCLUSIONS** 26

27 Switching diuretics to bedtime did promote nocturia, but only 15.6% found nocturia a major
28 burden. At 6-months, 77.3% of diuretic users were adherent to bedtime dosing. Bedtime
29 diuretic use is viable for most hypertensive patients, if indicated.
30
31
32
33
34

35 **TRIAL REGISTRATION** 36

37 NCT02990663
38
39

40 **Key Words:** Hypertension, diuretics, nocturia, chronotherapy, bedtime
41
42
43
44
45

46 **STENGTHS AND LIMITATIONS OF THIS STUDY** 47

- 48
49 • Our study question arises directly from members of the public who participated in the
50 design of the BedMed trial.
51
52
53
54
55
56
57
58
59
60

- Intervention and comparison groups were randomly selected from the same clinical trial population.
- Our data represent the first prospective evaluation of the tolerability of bedtime diuretics.
- Limitation: All participants were well established on morning antihypertensives at baseline. Those who previously tried and failed morning diuretics due to nocturia would be absent from the diuretic cohort. This could bias towards better bedtime diuretic tolerance.

INTRODUCTION

Although consensus is lacking,¹⁻³ two randomized trials by the same principal investigator suggest large reductions in major adverse cardiovascular events occur if blood pressure medications are taken at bedtime, as compared to conventional morning use.^{4,5} This finding, however, may be difficult to implement for those using diuretics - common first-line therapeutics, with a unique and important role in volume control and natriuresis.^{6,7} This is because diuretics are widely believed to promote nocturia, and typically recommended for morning use only as a result.^{8,9}

Nocturia occurs in roughly 2/3 of men and women over the age of 70 years¹⁰ and is believed to disrupt sleep, impair quality of life, and increase the risk of nighttime falls and fractures.^{11,12} However, there are no randomized trials examining diuretic timing and adverse

1
2
3 effects. The concern that bedtime diuretics could produce troublesome nocturia, being based
4
5 on opinion and observational data, could be incorrect. Morning diuretics (typically thiazides)
6
7 are generally well tolerated, and cross-sectional analysis of diuretic-using populations, without
8
9 accounting for administration time, does not support a strong association between diuretic use
10
11 and nocturia.^{13, 14} Whether clinicians can recommend diuretics for bedtime use is therefore
12
13 unclear.
14
15
16
17
18

19 To determine how well diuretics are tolerated at bedtime we conducted a pre-specified
20
21 prospective cohort study embedded within the ongoing BedMed trial. BedMed randomizes
22
23 Canadian primary care patients with hypertension to take their existing antihypertensive
24
25 medications either in the morning, or at bedtime, and examines mortality and morbidity
26
27 outcomes.¹⁵ Recruitment started in March 2017 and the trial is ongoing, with follow-up
28
29 continuing until late 2023. This paper examines those participants with a single morning
30
31 antihypertensive at baseline who were randomized to switch that antihypertensive to bedtime.
32
33 Our goal was to compare adherence with bedtime allocation, and self-reported nocturia
34
35 burden, between those switching a diuretic to bedtime, and those switching other types of
36
37 blood pressure lowering medication to bedtime. Note, our definition of adherence to allocation
38
39 time differs from the conventional notion. When we refer to adherence to bedtime allocation,
40
41 we are talking about the participant's *intention* to use their antihypertensive at bedtime. This
42
43 study is NOT evaluating the extent to which individual doses are missed. As such, we did not
44
45 compare bedtime diuretic use to morning diuretic use because morning medication use was
46
47 already well established for all participants. As we have defined it, we would expect virtually
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 everyone allocated to morning antihypertensives to be adherent to their administration time,
4
5 as a morning allocation meant no change of any kind was needed.
6
7
8
9
10

11 12 METHODS

13 14 15 16 **Study Design and Sample Size**

17
18 BedMed is an ongoing prospective, randomized, open, blinded-endpoint (PROBE)¹⁶ trial.
19
20 Recruitment is registry-like, with participating family physicians using their usual-care electronic
21
22 medical records to identify their eligible patients, and then mailing those patients information
23
24 about the study. Interested patients call the study team and, if eligible and consenting, are
25
26 randomized to take all their regular blood pressure medication (as tolerated) either in the
27
28 morning, or at bedtime. Participants received their allocation, using the REDCap¹⁷ server's
29
30 central randomization module, directly from a research assistant with no prior clinical
31
32 interactions, achieving irreversible, independent, and concealed allocation.
33
34
35
36
37

38 The prospective cohort study reported in this manuscript is a prespecified interim
39
40 analysis of BedMed data, carried out as part of an adaptive trial design. The analysis was
41
42 triggered upon the allocation to bedtime dosing of 203 participants whose only baseline
43
44 antihypertensive included a morning diuretic (whether a diuretic only, or a diuretic/non-
45
46 diuretic combination pill). If adherence with bedtime diuretic use had been poor, the BedMed
47
48 trial's inclusion criteria would have been altered to exclude future such individuals from
49
50 enrolling. This sample size gave a 90% chance of detecting a 20% relative reduction in
51
52 adherence to bedtime allocation if 1) morning adherence was 75%, and 2) there were an equal
53
54
55
56
57
58
59
60

1
2
3 number of participants switching a non-diuretic antihypertensive to bedtime with whom to
4
5 compare.
6
7
8
9

10 **Setting and Participants**

11
12 In Canada's publicly funded healthcare system, residents are not billed directly for physician
13 services, but medication costs are either paid for privately, or partially or completely covered by
14 either employer-sponsored health insurance, or government subsidized programs (including
15 coverage for seniors). The vast majority of Canadians have family physicians, who are normally
16 the sole prescriber of their patient's hypertension medications.
17
18
19
20
21
22
23

24
25 BedMed recruitment began in March 2017, with the final participant included in this
26 analysis enrolling in September 2020. Over this period, participants were being recruited by 352
27 family physicians (typical practice panel ~ 1,500 patients, with 20% hypertension prevalence
28 amongst adults) in the Canadian provinces of Alberta, Manitoba, British Columbia, and
29 Saskatchewan. Some BedMed participants (22% of those randomized) also learned about the
30 study through social media, or other sources, and were enrolled with their family physician's
31 consent, but without their family physician actively recruiting them. To be eligible for BedMed,
32 participants needed to be community dwelling (including assisted living), and to have a
33 physician diagnosis of hypertension for which they used one or more blood pressure-lowering
34 medications. BedMed excluded anyone with a personal history of glaucoma because of an
35 association between nocturnal hypotension and ischemic optic neuropathy in such
36 individuals.¹⁸⁻²¹ For this sub-study we intentionally kept our eligibility criteria as broad as
37 possible (including participants with potentially nocturia-modifying conditions like diabetes,
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sleep apnea, and congestive heart failure) so as to most closely resemble, and be generalizable
4
5
6 to, a hypertensive primary care population.
7
8
9

10 For this sub-study, the following inclusion and exclusion criteria defined the study cohort.
11
12

13 *Inclusion Criteria*

- 14
15 1. Physician diagnosis of hypertension
- 16
17 2. Only one antihypertensive pill in use at baseline (combination antihypertensive pills
18
19 permitted)
- 20
21 3. That single baseline antihypertensive pill was used in the morning at baseline, and only
22
23 once a day
- 24
25 4. The participant was randomized to switch that morning antihypertensive pill to bedtime
26
27
28
29
30
31

32 *Exclusion Criteria*

- 33
34 1. Participant did not attempt a medication timing change*
- 35
36 2. Physician changed the type of antihypertensive prior to the timing change*
- 37
38

39
40 *We made both these exclusions since, for the diuretic group, including patients who were
41
42 not actually attempting to switch a diuretic to bedtime would have lessened any potential
43
44 nocturia, and biased the groups towards looking more similar. When looking at adverse
45
46 effects of an intervention, such a “modified intention-to-treat” analysis is the more
47
48 conservative analytic option, given a full intention-to-treat analysis, for the reason
49
50 described above, is more likely to underestimate nocturia-related problems.
51
52
53
54
55
56
57
58
59
60

Procedures

Assistance Changing Antihypertensive Medication to Bedtime

Participants had their choice of being assisted in making their timing change by their family physician, who applied their own judgement as to how to make the change or, if they described no heart disease, by the research assistant with whom they were dialoging. Exceptions included those whose BP-lowering medication was Tiazac XC or Diltiazem XC (which have delayed-release kinetics), and furosemide, isosorbide mononitrate/dinitrate, or alpha blockers (medications whose timing decision may be more complicated). Such participants had their family physician guide their timing change. Advice from research assistants was to delay the next morning dose until bedtime, and to continue all future doses at bedtime. If bedtime use was problematic, switching to dinnertime was suggested. As a memory aid, participants were advised to place pill bottles near objects they use when getting ready for bed (e.g., toothbrush, denture case, alarm clock), or to use an AM/PM dosette.

Follow-up Interviews

Baseline characteristics were collected directly from participants through telephone interview prior to randomization. The first follow-up with a research assistant occurred by telephone 7-days post timing change to encourage adhering to the timing change, and to troubleshoot participant concerns. Another telephone follow-up took place at 6-weeks to obtain self-reported adherence to bedtime antihypertensive use (“Are you taking your blood pressure medication at bedtime?”; and if “no” - the reason for not doing so), and to assess nocturia. Participants could report nocturia as “no”, “minor”, or “major” burden (subjective overall

1
2
3 assessment, no itemized criteria), and they were asked to quantify the number of overnight
4
5 urinations per week by estimating the number of nights they rose to urinate, and the number of
6
7 times per night they urinated on those evenings. The same follow-up questions were asked
8
9 again at 6-months, either by telephone or by e-mail questionnaire (participant's choice), and
10
11 again every 6-months thereafter.
12
13

14
15 Note: this study was not designed to explore whether or not individual medication
16
17 doses were missed, something which could be better assessed with electronic devices, or pill
18
19 counting. We were instead assessing each participant's willingness to persist with bedtime
20
21 antihypertensive use. As such, self-report more accurately reflects the patient feedback
22
23 prescribers could expect, were they to recommend diuretics be administered at bedtime.
24
25
26
27
28
29

30 *Administrative Health Claims Data*

31
32 Comorbidities were also collected as baseline characteristics (coronary artery disease, diabetes,
33
34 sleep apnea, chronic kidney disease, chronic obstructive pulmonary disease (COPD), congestive
35
36 heart failure (CHF), and stroke). For non-Alberta residents, these comorbidities were self-
37
38 reported. For Alberta residents, the vast majority of participants (83%), these comorbidities
39
40 were derived from physician diagnoses submitted to Alberta Health in the normal course of
41
42 care, specifically, by extracting comorbidities from linked governmental databases recording
43
44 community physician billings and hospital separations. Access and analysis of this
45
46 administrative data was performed by Alberta Health Services, the governmental data steward.
47
48 These data, and this linking process, have been widely used in other studies and have been
49
50 identified as valid.²²⁻²⁵ Most comorbidities were considered present if there were two
51
52
53
54
55
56
57
58
59
60

1
2
3 community visits with that diagnosis, or one hospital diagnosis, from any physician. However
4
5 only one such diagnosis was required for stroke (since the diagnosis might not repeat outside of
6
7 the acute event), and for chronic kidney disease (which, in our experience, is infrequently
8
9 recorded by primary care providers).
10
11
12
13
14

15 **Outcomes** (as self-reported by participants)

16 *Primary*

- 17
18 1. Adherence to bedtime allocation at 6-months (nonadherence = changing back to morning,
19
20 stopping altogether, or switching antihypertensives)
21
22
23
24

25 *Secondary*

- 26
27 1. Adherence to bedtime allocation at 6-weeks
- 28
29 2. Nocturia considered to be a “major burden” at 6-weeks, and at 6-months (includes those
30
31 who report a major burden, and those who failed the timing change because of nocturia)
32
33
34
- 35
36 3. Number of overnight urinations per week at 6-weeks, and at 6-months
37
38
39

40 **Statistical Analysis**

41
42 Our inclusion and exclusion criteria created one prospective cohort with two exposures, 1) an
43
44 established morning diuretic medication being switched to bedtime, and 2) an established
45
46 morning non-diuretic medication being switched to bedtime. Participants using a combination
47
48 pill with two or more antihypertensive components were considered diuretic users if at least
49
50 one of those components was a diuretic. The analysis was by modified intention-to-treat and
51
52 consisted of descriptive statistics, comparing proportions using Fisher’s Exact Test (primary
53
54
55
56
57
58
59
60

1
2
3 outcome analysis), comparing the number of overnight urinations/week using Mann-Whitney,
4
5 and using Hodges-Lehmann estimation for difference in medians. All analyses utilized GraphPad
6
7 Prism version 9.1.2.
8
9

10 11 12 *Modified Intention-to-treat Assumptions*

- 13
14
15 1. Missing data: Missing variables were imputed using the value from the subsequent follow-
16
17 up interview. For example, if 6-week data were missing, adherence and nocturia burden
18
19 were assigned the 6-month value. If no subsequent data were available for imputation (i.e.,
20
21 loss to follow-up or study drop-out) participants were excluded from analysis. We did not
22
23 impute missing values for lost or dropped-out participants because we were looking to
24
25 demonstrate potential harm (harm constituting a difference in nonadherence or major
26
27 nocturia burden) and imputing missing values, being reasonably balanced between groups,
28
29 would have biased the groups towards looking more similar. Baseline characteristics of
30
31 those excluded from the primary analysis were compared to assess whether analysis
32
33 exclusion appeared random.
34
35
36
37
38
39
- 40 2. Medication changes: If nocturia resulted in participants switching medications, or
41
42 medication timing, we considered them non-adherent and to have a “major nocturia
43
44 burden”, even if a lesser degree of nocturia burden was reported at their follow-up
45
46 interview. Data from these non-adherent individuals was not used for assessment of
47
48 nocturia frequency. If medication or timing changes were made for reasons other than
49
50 nocturia, participants were excluded from analysis. We made this exclusion because
51
52
53
54
55
56
57
58
59
60

1
2
3 including such individuals would have biased the groups towards appearing more similar,
4
5 and could have led us to underestimate the nocturia burden in diuretic users.
6
7
8
9
10

11 **Patient and Public Involvement**

12 *Patient working group*

13
14
15
16
17 BedMed has a 10-member patient working group which began meeting in 2016 prior to the
18
19 recruitment of any participants. Working group members have participated in 1) the
20
21 construction of all participant facing materials, 2) the wording of research assistant follow-up
22
23 scripts, 3) decisions as to what data to collect, and 3) the hiring of research assistants.
24
25
26

27 *Patient-driven question*

28
29
30
31 The draft BedMed protocol was presented to a group of ~25 seniors in 2015, prior to grant
32
33 application and study registration. The question pursued in this manuscript derived directly
34
35 from this group's feedback, where concern was expressed that bedtime diuretics would be
36
37 poorly tolerated due to nocturia.
38
39
40
41
42
43
44

45 **RESULTS**

46
47
48 Of 579 eligible participants, 552 (95.3%) had analyzable data at 6-weeks, and 533 (92.1%) had
49
50 analyzable data at 6-months. This included, for our 6-month adherence primary outcome,
51
52 198/210 (94.3%) of the eligible diuretic users and 335/369 (90.8%) of the eligible non-diuretic
53
54 users. Individual reasons for exclusion are shown in Figure 1. A comparison of baseline
55
56
57
58
59
60

1
2
3 characteristics (eTable 1 of the online supplement), shows no notable differences between
4
5 those excluded from the primary outcome analysis, and those analyzed.
6
7

8 9 *Baseline*

10
11 Overall, most participants were from Alberta (83.0%), 94.7% identified as white, and they were
12
13 a mean 65.6 (STD 10.0) years of age. Baseline characteristics were comparable between groups
14
15 (Table 1) although slightly more diuretic users were female (65.5% vs 52.7%). They were largely
16
17 non-smokers (92.4%), exercised a median 3 (IQR 0-5) days/week, and had a median BMI of 28.3
18
19 (IQR 25.5-32.3). The most common comorbidities were coronary artery disease (19.2%), sleep
20
21 apnea (18.3%), and diabetes (17.2%). The cohort-defining medications used are broken down in
22
23 Figure 2. Of the diuretic users, 142 (70.0%) used a thiazide containing combination pill, and 42
24
25 (20.7%) used hydrochlorothiazide alone. Although BedMed does not collect information on
26
27 drug dosage, it would be unusual for Canadians to be prescribed hydrochlorothiazide outside a
28
29 range of 12.5 – 25 mg/day. Of the non-diuretic cohort, 150 (43.0%) used angiotensin receptor
30
31 blockers (ARB), 148 (42.4%) used angiotensin-converting enzyme inhibitors (ACEI), 38 (10.9%)
32
33 used calcium channel blockers (CCB), 4 (1.1%) used beta-blockers (BB), and 9 (2.6%) used
34
35 combination pills that did not include diuretics. Baseline nocturia was similar between diuretic
36
37 vs non-diuretic users, in terms of the number of overnight urinations per week (median 5.5 vs
38
39 6.0), and the percentage of participants perceiving nocturia to be a major burden (1.5% vs
40
41 2.3%). However slightly more diuretic users felt nocturia was a minor burden (30.5% vs 23.5%).
42
43
44 Overall, 3/4 of participants did experience nocturia at least once per week. Of these, 62.8%
45
46 considered it “not a problem”, 34.5% considered it “a minor problem”, and 2.6% considered it
47
48
49
50
51
52
53
54
55
56
57
58
59
60 “a major problem”.

Table 1. Baseline Characteristics

Characteristics	Diuretic (n=203) No. (%)	Non-Diuretic (n=349) No. (%)	p-value
Sex, female	133 (65.5)	184 (52.7)	0.004
Age, mean (STD), y	65.4 (8.9)	65.6 (10.6)	0.81
Province			
Alberta	169 (83.3)	289 (82.8)	0.99
British Columbia	14 (6.9)	37 (10.6)	0.17
Manitoba	16 (7.9)	19 (5.4)	0.23
Saskatchewan	4 (2.0)	4 (1.1)	0.47
Ethnicity			
White	195 (96.1)	328 (94.0)	0.33
South east asian	2 (1.0)	10 (2.9)	0.23
Asian	0	3 (0.8)	0.30
First nation	0	6 (1.7)	0.09
Black	0	0	0.99
Other	5 (2.5)	2 (0.6)	0.11
Decline to answer	1 (0.5)	0	0.37
Comorbidities ^a			
Coronary artery disease	39 (19.2)	67 (19.2)	0.99
Diabetes	31 (15.3)	64 (18.3)	0.41
Sleep apnea	38 (18.7)	63 (18.1)	0.91
Chronic kidney disease	14 (6.9)	39 (11.2)	0.13
COPD	16 (7.9)	35 (10.0)	0.45
Stroke	11 (5.4)	18 (5.2)	0.99
Heart failure	4 (2.0)	6 (1.7)	0.99
Cigarette smoker (current)	14 (6.9)	28 (8.0)	0.74
Physical exercise, median (IQR), days per week ^b	3 (1-5)	3 (0-5)	0.14
BMI, median (IQR), Kg/M ²	28.9 (26-33)	28.0 (25-32)	0.15
Underweight (< 18.5)	1 (0.5)	2 (0.6)	0.99
Normal weight (18.5 - 24.9)	35 (17.2)	74 (21.2)	0.27
Overweight (25 - 29.9)	84 (41.4)	143 (41.0)	0.93

Obese (≥ 30)	83 (40.9)	130 (37.2)	0.42
Nocturia, median (IQR), nocturnal urinations/wk	5.5 (1-10.5)	6.0 (1-10.5)	0.91
Does not experience nocturia	49 (24.1)	86 (24.6)	0.92
Nocturia occurs but "not a problem"	89 (43.8)	173 (49.6)	0.22
Nocturia "a minor problem"	62 (30.5)	82 (23.5)	0.07
Nocturia "a major problem"	3 (1.5)	8 (2.3)	0.75

^a Derived from Alberta provincial health claims data for 454 participants, and self-reported for 98.

^b "How many days in the past week have you exercised for 30 minutes or more, vigorously enough to raise your breathing rate?"

6-Weeks

Adherence with bedtime medication use was lower in diuretic users (88.7% vs 94.6%), but still high in both cohorts [difference 5.8%; 95%CI, 1.0% to 11.6%; $p = 0.02$; NNH 17.0] (Table 2).

Change in the number of overnight urinations per week could be calculated for 180 diuretic users, and 330 non-diuretic users (Figure 3). Compared to baseline, there were a median 1.0 more overnight urinations per week in diuretic users [95%CI, 0.0 to 1.5; $p < 0.0001$], and 9.9% more diuretic users perceived nocturia to be a major burden as compared with those who did not use diuretics [11.3% vs 1.4%; 95%CI Diff, 5.5% to 15.4%; $p < 0.0001$; Number Needed to Harm (NNH) 10.1] (Table 3).

6-Months

At 6-month, adherence to bedtime medication use (our primary outcome) had fallen somewhat in both groups (77.3% vs 89.8%), and the difference in adherence had widened [difference 12.6%; 95%CI Diff, 5.8% to 19.8%; $p < 0.0001$; NNH 8.0]. However most diuretic users were still adherent to bedtime medication use. Nocturia was given as the reason for nonadherence by 25/45 (55.6%) diuretic users, compared to 0/34 (0%) non-diuretic users, whose main reasons

1
2
3 for nonadherence were forgetting to take their pill (10/34, 29.4%), worsening of BP control
4
5 (8/34, 23.5%), and non-symptom driven medication changes (6/34, 17.6%). Of those still
6
7 adherent to allocation (153 diuretic users and 301 non-diuretic users), the median difference in
8
9 overnight urinations compared to baseline remained 1.0 urinations per week higher in diuretic
10
11 users, compared to non-diuretic users [95%CI, 0.0 to 1.75; p=0.012]. Including those who had
12
13 stopped adhering because of nocturia, 14.2% more diuretic users had perceived nocturia to be
14
15 a major burden [15.6% vs 1.3%; 95%CI Diff, 8.9% to 20.6%; p < 0.0001; NNH 7.0].
16
17
18
19
20

21 *Sex Differences*

22
23
24 Given slightly more diuretic users were female, we conducted a post-hoc analysis to determine
25
26 whether nocturia burden or adherence differed between sexes. Using the Mann-Whitney test
27
28 there was no difference, male vs female, in the number of overnight urinations at 6-weeks for
29
30 the diuretic group [median difference 0.0; 95%CI Diff, -1.0 to 1.0; p = 0.96], nor for the non-
31
32 diuretic group [median difference 0.0; 95%CI Diff, 0.0 to 0.0; p = 0.98]. Adherence with bedtime
33
34 antihypertensive use, diuretic vs non-diuretic users, was also similar between males and
35
36 females at 6-months [male: 76.5% vs 90.5%; female: 77.7% vs 89.3%; p = 0.86 for the difference
37
38 in adherence between male and female diuretic users]. The same was true for major nocturia
39
40 burden at 6-months, which was no different between sexes [male: 14.8% vs 0%; female: 16.0%
41
42 vs 2.5%; p > 0.99 for the difference in major nocturia burden between male and female diuretic
43
44 users].
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Non-adherence to Bedtime Allocation and Major Nocturia Burden, No. (%)

	Diuretic	Non-diuretic	Attributable Risk ^c (%) (95%CI)	p-value
6-weeks				
Major burden ^a	23/198 (11.6)	5/330 (1.5)	10.1 (5.6-15.7)	<0.0001
Nonadherence ^b	23/203 (11.3)	19/349 (5.4)	5.9 (1.0-11.6)	0.02
6-months				
Major burden ^a	28/180 (15.6)	4/301 (1.3)	14.2 (8.9-20.6)	<0.0001
Nonadherence ^b	45/198 (22.7)	34/335 (10.2)	12.6 (5.8-19.8)	<0.0001

^aIncludes those reporting major burden while using a bedtime diuretic, and those nonadherent due to nocturia. Data are number (%).

^bNonadherent for any reason. Data are number (%)

^cExcess risk of the outcome (noncompliance or major burden) for those in the diuretic group, compared to the non-diuretic group.

Table 3. Change in Number of Overnight Urinations per Week, median (IQR)

	Number of Overnight Urinations per Week		Median Change from Baseline		Between Group Difference Median (95%CI)	p-value
	Diuretic	Non-diuretic	Diuretic	Non-diuretic		
Baseline	5.5 (1.0-10.5)	6.0 (1.0-10.5)	-	-	0.0 ^{a,b} (0.0-0.0)	0.92
6-weeks	7.0 (2.6-11.6)	7.0 (1.5-10.5)	0.0 (0.0-3.5)	0.0 (-1.0-1.0)	1.0 ^{a,c} (0.0-1.5)	<0.0001
6-months	6.2 (0.0-10.5)	5.0 (0.0-10.5)	0.5 (-1.5-4.0)	0.0 (-2.0-2.0)	1.0 ^{a,d} (0.0-1.8)	0.01

^a The between group difference in medians is by Hodges–Lehmann estimation, hence this value differs from a simple subtraction of the diuretic and non-diuretic group medians provided

^b Between group difference for the median number of urinations per week at baseline

^c Between group difference for the median change from baseline at 6-weeks

^d Between group difference for the median change from baseline at 6-months

DISCUSSION

In this prospective cohort of hypertensive primary care patients, 1.5% of morning diuretic users experienced nocturia as a major burden at baseline. When these morning diuretic users switched their diuretic to bedtime, nocturia was more frequent, becoming a major burden for 15.6% of participants over a period of 6 months. Similar primary care patients simultaneously

1
2
3 switching other types of antihypertensives from morning to bedtime experienced no increase in
4
5 nocturia, but they still failed to adhere to bedtime use 10.2% of the time. Due to the extra
6
7 burden of nocturia, nonadherence in diuretic users was higher, at 22.7%. Hence 1 in 8 diuretic
8
9 users, compared to non-diuretic users, will fail the switch to bedtime, with 1 in 4 diuretic users
10
11 failing the switch overall.
12
13

14
15 Our findings are limited by the potential for selection bias, given some BedMed
16
17 participants may have previously tried diuretics (morning or evening) and, if they experienced
18
19 troublesome nocturia, may have stopped using diuretics altogether prior to enrolling. Morning
20
21 diuretic users may also have avoided enrolling in BedMed if they were concerned about the
22
23 possibility of needing to switch their diuretics to bedtime. The subjective nature of our
24
25 outcomes might also be considered a limitation, in that nocturia burden could be interpreted
26
27 differently by different people. However, self-reporting of nocturia burden integrates the
28
29 patient's perceptions and values, and our use of it prioritizes the individual's own assessment of
30
31 their experience. Our findings are simultaneously strengthened by the prospective nature of
32
33 the design, and by the cohort selection process, which ensured diuretic and non-diuretic users
34
35 were all recruited from the same practices, using the same approach, and meeting the same
36
37 inclusion and exclusion criteria.
38
39
40
41
42
43

44
45 To our knowledge, our study is the first to prospectively evaluate the link between
46
47 bedtime diuretic use and nocturia. Our finding the majority of diuretic users able to adhere to
48
49 bedtime use is consistent with the generally weak and variable association of diuretics and
50
51 nocturia in cross-sectional studies,^{11, 13} and the inability of baseline diuretics to predict future
52
53 nocturia (2-year incidence) in 1,289 community dwelling MESA study respondents 60 years and
54
55
56
57
58
59
60

1
2
3 older.²⁶ Although bedtime antihypertensive use might offer an advantage so far as
4
5 cardiovascular risk reduction,^{4,5} our clinical experience is that most BP-lowering medication is
6
7 still administered in the morning. In a 2017 survey of hypertensive primary care patients (single
8
9 center in Ohio, 139 respondents), 75.5% used all of their antihypertensive medication in the
10
11 morning.²⁷ Of the same population, 21 of 22 thiazide-diuretic users (95.5%) took that thiazide in
12
13 the morning.
14
15

16
17
18 Although roughly 14% of hypertensive primary care patients will newly experience
19
20 nocturia as a major burden after switching a thiazide diuretic from morning to bedtime, the
21
22 vast majority of morning diuretic users can successfully make the switch to bedtime should it
23
24 become clinically indicated to do so. The key remaining question is whether or not an attempt
25
26 to switch diuretics to bedtime is clinically indicated for cardiovascular risk reduction, as the
27
28 MAPEC and Hygia trials suggest.^{4,5} Three confirmatory trials, of which BedMed is one, are
29
30 currently underway,²⁸⁻³⁰ with one, the TIME trial,²⁸ recently reporting neither benefit, nor harm,
31
32 to bedtime prescribing at the Aug 2022 European Society of Cardiology Congress. Detailed
33
34 publication of the TIME findings are anticipated later this year, with BedMed expected to report
35
36 in mid 2024.
37
38
39
40
41
42
43
44

45 CONTRIBUTORS

46
47 SRG conceptualized the study. SRG, CSK, MRK, GMA, JAB, AGS, AK, FAM, RSP, RL, MDH, KM,
48
49 DPM, STW, JPM, LAG designed the study and obtained grant funding. SRG, CSK, MRK, GMA,
50
51 AGS, BGON, MGDPM, DAM, JEMK, JPMA recruited physicians for the study. SRG supervised the
52
53 conduct of the trial. MDK and JMSY prepared the study data. SRG and MDK analyzed the data.
54
55
56
57
58
59
60

1
2
3 SRG and MDK wrote the draft manuscript. All authors contributed to critical revision of the
4
5 manuscript, and all authors approved the final manuscript. SRG is the guarantor. The
6
7 corresponding author attests that all listed authors meet authorship criteria and that no others
8
9 meeting the criteria have been omitted.
10
11
12
13
14

15 COMPETING INTERESTS

16
17 All authors have completed the ICMJE uniform disclosure form at
18
19 <https://www.icmje.org/disclosure-of-interest/> and declare: SRG is the nominated principal
20
21 applicant of two grants from governmental sources that are funding the BedMed trial (from
22
23 Alberta Innovates, and the Canadian Institutes of Health Research); RSP is CEO of “mmHg Inc”,
24
25 a digital health company and maker of software solutions for BP monitoring; MDH is the
26
27 recipient of several grants from pharmaceutical and device companies related to interventions
28
29 geared at stroke treatment. He holds two device patents related to stroke imaging, has chaired
30
31 or sat on the Data Safety Monitoring Boards of 5 other cardiovascular trials, is the President of
32
33 the Canadian Neurological Sciences Federation, a member of the board of the Canadian Stroke
34
35 Consortium, and has private stock ownership in two companies targeting imaging interventions
36
37 (Circle Inc, and PureWeb Inc).
38
39
40
41
42
43
44
45
46
47

48 FUNDING

49
50 BedMed is funded by a Support for Patient Oriented Research (SPOR) Innovative Clinical Trial
51
52 Multi-Year Grant (REF#: 151212) from the Canadian Institutes of Health Research (CIHR), and
53
54 from a Partnership for Research and Innovation in the Health System (PRIHS) Grant from
55
56
57
58
59
60

1
2
3 Alberta Innovates (REF#: 201 500 912 G2019000450). It also received in-kind research
4
5 assistance from Enhancing Alberta Primary Care Research Networks (EnACT), which itself is
6
7 funded entirely by Alberta Innovates, and received pilot funding from the Northern Alberta
8
9 Family Medicine Fund (University of Alberta Dept of Family Medicine funding).
10
11
12
13
14

15 DATA SHARING

16
17
18 De-identified patient level data upon which this analysis is based will be freely available for
19
20 download at www.PragmaticTrials.ca following publication.
21
22
23
24

25 ETHICAL APPROVAL

26
27
28 All procedures and methods were approved by the clinical research ethics boards of the
29
30 Universities of Alberta (Pro00045958), Calgary (REB17-1887), British Columbia (H21-00523),
31
32 Saskatchewan (1421), and Manitoba (HS20852:B2017:08).
33
34
35
36
37

38 COPYRIGHT/LICENCE FOR PUBLICATION

39
40
41 The Corresponding Author has the right to grant on behalf of all authors and does grant on
42
43 behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all
44
45 forms, formats and media (whether known now or created in the future), to i) publish,
46
47 reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
48
49 other languages, create adaptations, reprints, include within collections and create summaries,
50
51 extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on
52
53 the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of
54
55
56
57
58
59
60

1
2
3 electronic links from the Contribution to third party material where-ever it may be located; and,
4
5
6 vi) licence any third party to do any or all of the above.
7
8
9

10 References

- 13 1. Turgeon RD, Althouse AD, Cohen JB, Enache B, Hogenesch JB, Johansen ME, et al. Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: Controversies in hypertension - con side of the argument. *Hypertension*. 2021;78:871-878
- 14 2. Kreutz R, Kjeldsen SE, Burnier M, Narkiewicz K, Oparil S, Mancia G. Disregard the reported data from the hygia project: Blood pressure medication not to be routinely dosed at bedtime. *J Hypertens*. 2020;38:2144-2145
- 15 3. Carlsberg B, Brunstrom B. Is bedtime the best time of day? *International Society of Hypertension March 2020 Newsletter* <https://ish-world.com/data/uploads/2003-1.pdf#page=19> Accessed Dec 17 2021
- 16 4. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the mapec study. *Chronobiol Int*. 2010;27:1629-1651
- 17 5. Hermida RC, Crespo JJ, Dominguez-Sardina M, Otero A, Moya A, Rios MT, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: The hygia chronotherapy trial. *European heart journal*. 2020;41:4565-4576
- 18 6. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. *Can J Cardiol*. 2020;36:596-624
- 19 7. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. *Cochrane Database Syst Rev*. 2018;4:CD001841
- 20 8. WebMD. Diuretics (water pills) for high blood pressure <https://www.webmd.com/hypertension-high-blood-pressure/guide/diuretic-treatment-high-blood-pressure> Accessed Jul 1 2021
- 21 9. Heart and Stroke Foundation of Canada. Diuretics <https://www.heartandstroke.ca/heart-disease/treatments/medications/diuretics> Accessed Jul 1 2021
- 22 10. Bosch JL, Weiss JP. The prevalence and causes of nocturia. *J Urol*. 2010;184:440-446
- 23 11. Asplund R. Nocturia in relation to sleep, health, and medical treatment in the elderly. *BJU Int*. 2005;96 Suppl 1:15-21
- 24 12. Ali A, Snape J. Nocturia in older people: A review of causes, consequences, assessment and management. *Int J Clin Pract*. 2004;58:366-373
- 25 13. Rembratt A, Norgaard JP, Andersson KE. Nocturia and associated morbidity in a community-dwelling elderly population. *BJU Int*. 2003;92:726-730

14. Asplund R, Aberg H. Health of the elderly with regard to sleep and nocturnal micturition. *Scand J Prim Health Care*. 1992;10:98-104
15. Garrison SR, Kolber MR, Allan GM, Bakal J, Green L, Singer A, et al. Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (bedmed): Protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. *BMJ Open*. 2022;12:e059711
16. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (probe) study. A novel design for intervention trials. Prospective randomized open blinded end-point. *Blood Press*. 1992;1:113-119
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (redcap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377-381
18. Grieshaber MC, Flammer J. Blood flow in glaucoma. *Curr Opin Ophthalmol*. 2005;16:79-83
19. Hayreh SS. Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension. *Curr Opin Ophthalmol*. 1999;10:474-482
20. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. *Am J Ophthalmol*. 1994;117:603-624
21. Krasinska B, Karolczak-Kulesza M, Krasinski Z, Pawlaczyk-Gabriel K, Lopatka P, Gluszek J, et al. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. *Blood Press*. 2012;21:240-248
22. Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, et al. Methods for identifying 30 chronic conditions: Application to administrative data. *BMC Med Inform Decis Mak*. 2015;15:31
23. Roos LL, Gupta S, Soodeen RA, Jebamani L. Data quality in an information-rich environment: Canada as an example. *Can J Aging*. 2005;24 Suppl 1:153-170
24. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. *Stroke; a journal of cerebral circulation*. 2005;36:1776-1781
25. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in icd-9-cm and icd-10 administrative data. *Med Care*. 2005;43:1130-1139
26. Johnson TM, 2nd, Sattin RW, Parmelee P, Fultz NH, Ouslander JG. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. *J Am Geriatr Soc*. 2005;53:1011-1016
27. Perry LA, Surowiec S M, Danso DA, Kerobo OI, Anugwom AA, Couvertier KP. Evaluation of administration time and adherence rates of morning vs. Bedtime dosing of antihypertensive medications. *Journal of Contemporary Pharmacy Practice*. 2019;66:11-16
28. Rorie DA, Rogers A, Mackenzie IS, Ford I, Webb DJ, Willams B, et al. Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning

- 1
2
3 versus evening dosing in hypertensive patients: The treatment in morning versus
4 evening (time) study. *BMJ Open*. 2016;6:e010313
5
6 29. Garrison S. The effect of antihypertensive medication timing on morbidity and mortality.
7 National institutes of health clinical trials
8 registry. <https://www.clinicaltrials.gov/ct2/show/NCT02990663> Accessed Jan 12 2021
9
10 30. Garrison SR. Bedmed-frail: Does the potential benefit of bedtime antihypertensive
11 prescribing extend to frail populations? National institutes of health clinical trials
12 registry. <https://www.clinicaltrials.gov/ct2/show/NCT04054648> Accessed Jan 12 2021
13
14
15
16
17

18 FIGURE LEGENDS

19
20 Figure 1:

21
22 Figure 1 Study flow diagram for analysis of adherence
23
24
25
26
27

28 Figure 2:

29
30 Figure 2 Medication frequency at baseline. HCTZ = hydrochlorothiazide
31
32
33
34

35 Figure 3:

36
37 Figure 3 6-week change in overnight urinations per week. Figure is the change in the number of
38 overnight urinations per week experienced by hypertensive primary care patients 6-weeks after
39 being randomly allocated to switch their only blood pressure lowering pill from morning to
40 bedtime. Grouped by those whose pill contained a diuretic (90.7% of which were thiazides), and
41 those who used a different class of blood pressure lowering medication.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Study flow diagram for analysis of adherence

163x190mm (150 x 150 DPI)




Figure 2 Medication frequency at baseline. HCTZ = hydrochlorothiazide

154x200mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 6-week change in overnight urinations per week. Figure is the change in the number of overnight urinations per week experienced by hypertensive primary care patients 6-weeks after being randomly allocated to switch their only blood pressure lowering pill from morning to bedtime. Grouped by those whose pill contained a diuretic (90.7% of which were thiazides), and those who used a different class of blood pressure lowering medication.

165x116mm (150 x 150 DPI)

Tolerability of Bedtime Diuretics: A Prospective Cohort Analysis (Supplementary Information)

eTable 1. Comparison of baseline characteristics for participants that were excluded vs. included in the primary outcome analysis

Characteristics	Excluded (n=46) No. (%)	Included (n=533) No. (%)	p-value
Sex, female	27 (58.7)	308 (57.8)	0.99
Province			
Alberta	39 (84.8)	442 (82.9)	0.84
British Columbia	4 (8.7)	48 (9.0)	0.99
Manitoba	2 (4.4)	35 (6.6)	0.76
Saskatchewan	1 (2.2)	8 (1.5)	0.53
Rural resident	4 (8.7)	71 (13.3)	0.49
Age, mean (STD), y	64.6 (10.6)	65.5 (10.0)	0.55
≤ 29	0	1 (0.2)	0.99
30 - 39	0	2 (0.4)	0.99
40 - 49	3 (6.5)	24 (4.5)	0.46
50 - 59	9 (19.6)	116 (21.8)	0.85
60 - 69	18 (39.1)	202 (37.9)	0.87
70 - 79	11 (23.9)	146 (27.4)	0.73
80 - 89	5 (10.9)	39 (7.3)	0.38
≥ 90	0	3 (0.6)	0.99
Ethnicity			
White	43 (93.5)	504 (94.6)	0.73
South east asian	0	12 (2.3)	0.61
Asian	1 (2.2)	3 (0.6)	0.28
First nation	0	6 (1.1)	0.99
Black	0	0	0.99
Other	1 (2.2)	7 (1.3)	0.49
Decline to answer	1 (2.2)	1 (0.2)	0.15

Education level			
Less than high school	4 (8.7)	21 (3.9)	0.13
High school diploma	19 (41.3)	147 (27.6)	0.06
Technical or trade college diploma	9 (19.6)	146 (27.4)	0.30
University degree	13 (28.3)	219 (41.1)	0.12
Decline to answer	1 (2.2)	0	0.08
Annual household income, CAD\$			
< 25,000	4 (8.7)	25 (4.7)	0.28
25,000 to 100,000	20 (43.5)	287 (53.8)	0.22
> 100,000	20 (43.5)	189 (35.5)	0.34
Decline to answer	2 (4.4)	32 (6.0)	0.99
Comorbidities ^a			
Coronary artery disease	9 (19.6)	100 (18.8)	0.85
Diabetes	6 (13)	92 (17.3)	0.54
Sleep apnea	11 (23.9)	99 (18.6)	0.43
Chronic kidney disease	7 (15.2)	48 (9.0)	0.19
COPD	6 (13.0)	50 (9.4)	0.43
Stroke	1 (2.2)	28 (5.3)	0.72
Heart failure	0	10 (1.9)	0.99
Hip fracture	1 (2.2)	2 (0.4)	0.22
Cigarette smoker (current)	2 (4.4)	42 (7.9)	0.56
Nocturia, median (IQR), nocturnal urinations/wk	7 (0-14.0)	6 (1-10.5)	0.61
Does not experience nocturia	12 (26.1)	129 (24.2)	0.72
Nocturia occurs but "not a problem"	21 (45.6)	255 (47.8)	0.88
Nocturia "a minor problem"	12 (26.1)	139 (26.1)	0.99
Nocturia "a major problem"	1 (2.2)	10 (1.9)	0.60
Physical exercise, median (IQR), days per week ^b	3 (0-5.0)	3 (0.5-5.0)	0.42
0	15 (32.6)	133 (25.0)	0.29
1	6 (13.0)	43 (8.1)	0.26
2	1 (2.2)	68 (12.8)	0.03
3	6 (13.0)	75 (14.1)	0.99
4	6 (13.0)	54 (10.1)	0.46
5	2 (4.4)	49 (9.2)	0.41

6	1 (2.2)	15 (2.8)	0.99
7	9 (19.6)	96 (18.0)	0.84
BMI, median (IQR), Kg/M ²	27.7 (26.1-33.4)	28.3 (25.5-32.3)	0.80
Underweight (< 18.5)	0	3 (0.6)	0.99
Normal weight (18.5 - 24.9)	9 (19.6)	105 (19.7)	0.99
Overweight (25 - 29.9)	21 (45.7)	220 (41.3)	0.64
Obese (≥ 30)	16 (34.8)	205 (38.5)	0.75
EQ-5D-5L overall health score, median (IQR) ^c	80 (75-90)	80 (75-90)	0.88
Physically frail ^d	7 (15.2)	73 (13.7)	0.82
Cognition ^e			
Normal	41 (89.1)	496 (93.1)	0.37
Questionable impairment	3 (6.5)	36 (6.8)	0.99
Impairment consistent with dementia	2 (4.4)	1 (0.2)	0.02

^a Derived from Alberta provincial health claims data and self-report.

^b "How many days in the past week have you exercised for 30 minutes or more, vigorously enough to raise your breathing rate?"

^c Self-rating of overall health on a scale of 0 (worst) to 100 (best).

^d As per Tilburg Frailty Indicator's physical sub-scale (sub-scale score ≥3 defines physically frail).

^e As per Short Blessed screening test score. Considered to be normal (0-4), questionable impairment (5-9), or impairment consistent with dementia (>9).

BMJ Open

Tolerability of bedtime diuretics: A prospective cohort analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-068188.R1
Article Type:	Original research
Date Submitted by the Author:	06-Apr-2023
Complete List of Authors:	<p>Garrison, Scott; University of Alberta Faculty of Medicine & Dentistry, Family Medicine; University of Alberta, Pragmatic Trials Collaborative Kelmer, Michael; University of Alberta, Faculty of Nursing; University of Alberta, Pragmatic Trials Collaborative Korownyk, Tina ; University of Alberta Faculty of Medicine & Dentistry, Family Medicine; University of Alberta, Pragmatic Trials Collaborative Kolber, Michael; University of Alberta Faculty of Medicine & Dentistry, Family Medicine; University of Alberta, Pragmatic Trials Collaborative Allan, Gary; College of Family Physicians of Canada, Programs and Practice Support; University of Alberta, Pragmatic Trials Collaborative Bakal, Jeffrey; Alberta Health Services, Provincial Research Data Services Singer , Alexander; University of Manitoba, Family Medicine Katz, Alan; University of Manitoba, Community Health Sciences Mcalister, Finlay; University of Alberta Faculty of Medicine & Dentistry, Medicine Padwal, Raj S ; University of Alberta Faculty of Medicine & Dentistry, Medicine Lewanczuk, Richard; University of Alberta Faculty of Medicine & Dentistry, Medicine Hill, Michael; University of Calgary Cumming School of Medicine, Clinical Neurosciences McGrail, Kimberlyn; The University of British Columbia, School of Population and Public Health O'Neill, Braden; University of Toronto, Family and Community Medicine Greiver, Michelle; University of Toronto, Family and Community Medicine Manca, Donna; University of Alberta Faculty of Medicine & Dentistry, Family Medicine Mangin, Dee; McMaster University Faculty of Health Sciences, Family Medicine Wong, Sabrina T.; The University of British Columbia, School of Population and Public Health Kirkwood, Jessica; University of Alberta Faculty of Medicine & Dentistry, Family Medicine McCormack, James; The University of British Columbia, Faculty of Pharmaceutical Sciences Yeung, Jack; Alberta Health Services, Provincial Research Data Services Green, Lee ; University of Alberta Faculty of Medicine & Dentistry, Family Medicine</p>
Primary Subject	Cardiovascular medicine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Heading	
Secondary Subject Heading:	Pharmacology and therapeutics, General practice / Family practice, Urology
Keywords:	Hypertension < CARDIOLOGY, CLINICAL PHARMACOLOGY, PRIMARY CARE, Cardiology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Tolerability of bedtime diuretics: A prospective cohort analysis

Scott R Garrison, Professor;^{1,2} Michael D Kelmer, student;^{1,2} Tina Korownyk, Professor;^{1,2} Michael R Kolber Professor;^{1,2} G Michael Allan, Professor;^{1,3} Jeffrey A Bakal, Program Director;⁴ Alexander G Singer, Associate Professor;⁵ Alan Katz, Professor;⁵ Finlay A McAlister, Professor;⁶ Raj S Padwal, Professor;⁶ Richard Lewanczuk, Professor;⁶ Michael D Hill, Professor;⁷ Kimberlyn McGrail, Professor;^{8,9} Braden G O'Neill, Assistant Professor;¹⁰ Michelle Greiver, Associate Professor;¹⁰ Donna P Manca, Professor;² Dee A Mangin, Professor;¹¹ Sabrina T Wong, Professor;^{9,12} Jessica EM Kirkwood, Assistant Professor;^{1,2} James P McCormack, Professor;¹³ Jack MS Yeung, Programmer;⁴ Lee A Green, Professor.^{1,2}

¹Pragmatic Trials Collaborative, University of Alberta, Edmonton, AB; ²Dept of Family Medicine, University of Alberta, Edmonton, AB; ³College of Family Physicians of Canada; ⁴Provincial Research Data Services, Alberta Health Services, Edmonton, AB; ⁵Dept of Family Medicine, University of Manitoba, Winnipeg, MB; ⁶Dept of Medicine, University of Alberta, Edmonton, AB; ⁷Cumming School of Medicine, University of Calgary, Calgary, AB; ⁸School of Population and Public Health, University of Alberta, Edmonton, AB; ⁹Centre for Health Services and Policy research, Vancouver, BC; ¹⁰Dept of Family and Community Medicine, University of Toronto, Toronto, ON; ¹¹McMaster University, Hamilton, ON; ¹²School of Nursing, University of British Columbia, Vancouver, BC; ¹³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC

Corresponding Author:

Scott R Garrison MD, PhD, CCFP; 6-60 University Terrace, University of Alberta, Edmonton, Alberta, Canada, T6G 2T4; Phone: 587-785-3012; Email: scott.garrison@ualberta.ca

Co-authors:

Michael Kelmer kelmer@ualberta.ca
 Tina Korownyk cpoag@ualberta.ca
 Michael Kolber mkolber@ualberta.ca
 G Michael Allan mgallan@ualberta.ca
 Jeffrey Bakal jbakal@ualberta.ca
 Alex Singer alexandersinger@gmail.com
 Alan Katz Alan_Katz@cpe.umanitoba.ca
 Finlay McAlister finlay.mcalister@ualberta.ca
 Raj Padwal rpadwal@ualberta.ca
 Richard Lewanczuk rlewancz@ualberta.ca
 Michael Hill michael.hill@ucalgary.ca
 Kimberlyn McGrail kim.mcgrail@ubc.ca

Braden O'Neill braden.oneill@gmail.com
 Michelle Greiver Michelle.Greiver@nygh.on.ca
 Donna Manca dpmanca@ualberta.ca
 Dee Mangin mangind@mcmaster.ca
 Sabrina Wong sabrina.wong@ubc.ca
 Jessica Kirkwood jek5@ualberta.ca
 James McCormack james.mccormack@ubc.ca
 Jack Yeung ManShun.Yeung@albertahealthservices.ca
 Lee Green lagreen@ualberta.ca

ABSTRACT

OBJECTIVES

We sought to validate, or refute, the common belief that bedtime diuretics are poorly tolerated due to nocturia.

DESIGN

Prespecified prospective cohort analysis embedded within the randomized BedMed trial, in which hypertensive participants are randomized to morning vs. bedtime antihypertensive administration.

SETTING

352 community family practices across 4 Canadian provinces between March 2017 and September 2020.

PARTICIPANTS

552 hypertensive patients (65.6 years old, 57.4% female) already established on a single once-daily morning antihypertensive and randomized to switch that antihypertensive to bedtime. Of these, 203 used diuretics (27.1% thiazide alone, 70.0% thiazide/non-diuretic combinations) and 349 used non-diuretics.

INTERVENTION

Switching the established antihypertensive from morning to bedtime, and comparing the experience of diuretic and non-diuretic users.

PRIMARY AND SECONDARY OUTCOME MEASURES

PRIMARY OUTCOME: Adherence to bedtime allocation time at 6-months (defined as the willingness to continue with bedtime use, not an assessment of missed doses). SECONDARY 6-

1
2
3 MONTH OUTCOMES: 1) Nocturia considered to be a major burden, 2) Increase in overnight
4 urinations/week. All outcomes were self-reported, and additionally collected at 6-weeks.
5
6

7 8 **RESULTS** 9

10 At 6-months: Adherence to bedtime allocation time was lower in diuretic users than non-
11 diuretic users [77.3% vs 89.8%; difference 12.6%; 95%CI 5.8% to 19.8%; $p < 0.0001$; NNH 8.0],
12 and more diuretic users considered nocturia a major burden [15.6% vs 1.3%; difference 14.2%;
13 95%CI 8.9% to 20.6%; $p < 0.0001$; NNH 7.0]. Compared to baseline, diuretic users experienced
14
15 1.0 more overnight urinations/week [95%CI 0.0 to 1.75; $p = 0.01$]. Results did not differ
16
17 between sexes.
18
19
20
21
22
23

24 25 **CONCLUSIONS** 26

27 Switching diuretics to bedtime did promote nocturia, but only 15.6% found nocturia a major
28 burden. At 6-months, 77.3% of diuretic users were adherent to bedtime dosing. Bedtime
29 diuretic use is viable for many hypertensive patients, should it ever become clinically indicated.
30
31
32
33
34

35 **TRIAL REGISTRATION** 36

37 NCT02990663
38
39

40 **Key Words:** Hypertension, diuretics, nocturia, chronotherapy, bedtime
41
42
43
44
45

46 **STENGTHS AND LIMITATIONS OF THIS STUDY** 47

- 48
49 • Our study question arises directly from members of the public who participated in the
50 design of the BedMed trial.
51
52
53
54
55
56
57
58
59
60

- Intervention and comparison groups were randomly selected from the same clinical trial population.
- Our data represent the first prospective evaluation of the tolerability of bedtime diuretics.
- Limitation: Those who previously tried and failed morning diuretics due to nocturia would be absent from the diuretic cohort, which could bias towards better bedtime diuretic tolerance.

INTRODUCTION

Although consensus is lacking,¹⁻³ two randomized trials by the same principal investigator suggest large reductions in major adverse cardiovascular events occur if blood pressure medications are taken at bedtime, as compared to conventional morning use.^{4,5} This finding, however, may be difficult to implement for those using diuretics - common first-line therapeutics, with a unique and important role in volume control and natriuresis.^{6,7} This is because diuretics are widely believed to promote nocturia, and typically recommended for morning use only as a result.^{8,9}

Nocturia occurs in roughly 2/3 of men and women over the age of 70 years¹⁰ and is believed to disrupt sleep, impair quality of life, and increase the risk of nighttime falls and fractures.^{11,12} However, there are no randomized trials examining diuretic timing and adverse effects. The concern that bedtime diuretics could produce troublesome nocturia, being based

1
2
3 on opinion and observational data, could be incorrect. Morning diuretics (typically thiazides)
4
5 are generally well tolerated, and cross-sectional analysis of diuretic-using populations, without
6
7 accounting for administration time, does not support a strong association between diuretic use
8
9 and nocturia.^{13, 14} Whether clinicians can recommend diuretics for bedtime use is therefore
10
11 unclear.
12
13
14
15

16 To determine how well diuretics are tolerated at bedtime we conducted a pre-specified
17
18 prospective cohort study embedded within the ongoing BedMed trial. BedMed randomizes
19
20 Canadian primary care patients with hypertension to take their existing antihypertensive
21
22 medications either in the morning, or at bedtime, and examines mortality and morbidity
23
24 outcomes.¹⁵ Recruitment started in March 2017 and the trial is ongoing, with follow-up
25
26 continuing until late 2023. This paper examines those participants with a single morning
27
28 antihypertensive at baseline who were randomized to switch that antihypertensive to bedtime.
29
30 Our goal was to compare adherence with bedtime allocation, and self-reported nocturia
31
32 burden, between those switching a diuretic to bedtime, and those switching other types of
33
34 blood pressure lowering medication to bedtime. Note, our definition of adherence to allocation
35
36 time differs from the conventional notion. When we refer to adherence to bedtime allocation,
37
38 we are talking about the participant's *intention* to use their antihypertensive at bedtime. This
39
40 study is NOT evaluating the extent to which individual doses are missed. As such, we did not
41
42 compare bedtime diuretic use to morning diuretic use because morning medication use was
43
44 already well established for all participants. As we have defined it, we would expect virtually
45
46 everyone allocated to morning antihypertensives to be adherent to their administration time,
47
48 as a morning allocation meant no change of any kind was needed.
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Study Design and Sample Size

BedMed is an ongoing prospective, randomized, open, blinded-endpoint (PROBE)¹⁶ trial.

Recruitment is registry-like, with participating family physicians using their usual-care electronic medical records to identify their eligible patients, and then mailing those patients information about the study. Interested patients call the study team and, if eligible and consenting, are randomized to take all their regular blood pressure medication (as tolerated) either in the morning, or at bedtime. Participants received their allocation, using the REDCap¹⁷ server's central randomization module, directly from a research assistant with no prior clinical interactions, achieving irreversible, independent, and concealed allocation.

The prospective cohort study reported in this manuscript is a prespecified interim analysis of BedMed data, carried out as part of an adaptive trial design. The analysis was triggered upon the allocation to bedtime dosing of 203 participants whose only baseline antihypertensive included a morning diuretic (whether a diuretic only, or a diuretic/non-diuretic combination pill). If adherence with bedtime diuretic use had been poor, the BedMed trial's inclusion criteria would have been altered to exclude future such individuals from enrolling. This sample size gave a 90% chance of detecting a 20% relative reduction in adherence to bedtime allocation if 1) morning adherence was 75%, and 2) there were an equal number of participants switching a non-diuretic antihypertensive to bedtime with whom to compare.

Setting and Participants

In Canada's publicly funded healthcare system, residents are not billed directly for physician services, but medication costs are either paid for privately, or partially or completely covered by either employer-sponsored health insurance, or government subsidized programs (including coverage for seniors). The vast majority of Canadians have family physicians, who are normally the sole prescriber of their patient's hypertension medications.

BedMed recruitment began in March 2017, with the final participant included in this analysis enrolling in September 2020. Over this period, participants were being recruited by 352 family physicians (typical practice panel ~ 1,500 patients, with 20% hypertension prevalence amongst adults) in the Canadian provinces of Alberta, Manitoba, British Columbia, and Saskatchewan. Some BedMed participants (22% of those randomized) also learned about the study through social media, or other sources, and were enrolled with their family physician's consent, but without their family physician actively recruiting them. To be eligible for BedMed, participants needed to be community dwelling (including assisted living), and to have a physician diagnosis of hypertension for which they used one or more blood pressure-lowering medications. BedMed excluded anyone with a personal history of glaucoma because of an association between nocturnal hypotension and ischemic optic neuropathy in such individuals.¹⁸⁻²¹ For this sub-study we intentionally kept our eligibility criteria as broad as possible (including participants with potentially nocturia-modifying conditions like diabetes, sleep apnea, and congestive heart failure) so as to most closely resemble, and be generalizable to, a hypertensive primary care population.

1
2
3
4
5
6 For this sub-study, the following inclusion and exclusion criteria defined the study cohort.
7

8 *Inclusion Criteria*
9

- 10
11 1. Physician diagnosis of hypertension
12
13 2. Only one antihypertensive pill in use at baseline (combination antihypertensive pills
14 permitted)
15
16 3. That single baseline antihypertensive pill was used in the morning at baseline, and only
17 once a day
18
19 4. The participant was randomized to switch that morning antihypertensive pill to bedtime
20
21
22
23
24
25
26

27 *Exclusion Criteria*
28

- 29
30 1. Participant did not attempt a medication timing change*
31
32 2. Physician changed the type of antihypertensive prior to the timing change*
33
34

35 *We made both these exclusions since, for the diuretic group, including patients who were
36 not actually attempting to switch a diuretic to bedtime would have lessened any potential
37 nocturia, and biased the groups towards looking more similar. When looking at adverse
38 effects of an intervention, such a “modified intention-to-treat” analysis is the more
39 conservative analytic option, given a full intention-to-treat analysis, for the reason
40 described above, is more likely to underestimate nocturia-related problems.
41
42
43
44
45
46
47
48
49
50

51
52 **Procedures**
53

54 *Assistance Changing Antihypertensive Medication to Bedtime*
55
56
57
58
59
60

1
2
3 Participants had their choice of being assisted in making their timing change by their family
4
5 physician, who applied their own judgement as to how to make the change or, if they described
6
7 no heart disease, by the research assistant with whom they were dialoging. Exceptions included
8
9 those whose BP-lowering medication was Tiazac XC or Diltiazem XC (which have delayed-
10
11 release kinetics), and furosemide, isosorbide mononitrate/dinitrate, or alpha blockers
12
13 (medications whose timing decision may be more complicated). Such participants had their
14
15 family physician guide their timing change. Advice from research assistants was to delay the
16
17 next morning dose until bedtime, and to continue all future doses at bedtime. If bedtime use
18
19 proved problematic, and there was concern participants would switch back to morning,
20
21 switching to dinnertime was suggested. As a memory aid, participants were advised to place pill
22
23 bottles near objects they use when getting ready for bed (e.g., toothbrush, denture case, alarm
24
25 clock), or to use an AM/PM dosette.
26
27
28
29
30
31
32
33
34

35 *Follow-up Interviews*

36
37 Baseline characteristics were collected directly from participants through telephone interview
38
39 prior to randomization. The first follow-up with a research assistant occurred by telephone 7-
40
41 days post timing change to encourage adhering to the timing change, and to troubleshoot
42
43 participant concerns. Another telephone follow-up took place at 6-weeks to obtain self-
44
45 reported adherence to bedtime antihypertensive use (“Are you taking your blood pressure
46
47 medication at bedtime?”; and if “no” - the reason for not doing so), and to assess nocturia.
48
49 Participants could report nocturia as “no”, “minor”, or “major” burden (subjective overall
50
51 assessment, no itemized criteria), and they were asked to quantify the number of overnight
52
53
54
55
56
57
58
59
60

1
2
3 urinations per week by estimating the number of nights they rose to urinate, and the number of
4
5 times per night they urinated on those evenings. The same follow-up questions were asked
6
7 again at 6-months, either by telephone or by e-mail questionnaire (participant's choice), and
8
9 again every 6-months thereafter.
10
11

12
13 Note: this study was not designed to explore whether or not individual medication
14
15 doses were missed, something which could be better assessed with electronic devices, or pill
16
17 counting. We were instead assessing each participant's willingness to persist with bedtime
18
19 antihypertensive use. As such, self-report more accurately reflects the patient feedback
20
21 prescribers could expect, were they to recommend diuretics be administered at bedtime.
22
23
24
25
26
27

28 *Administrative Health Claims Data*

29
30 Comorbidities were also collected as baseline characteristics (coronary artery disease, diabetes,
31
32 sleep apnea, chronic kidney disease, chronic obstructive pulmonary disease (COPD), congestive
33
34 heart failure (CHF), and stroke). For non-Alberta residents, these comorbidities were self-
35
36 reported. For Alberta residents, the vast majority of participants (83%), these comorbidities
37
38 were derived from physician diagnoses submitted to Alberta Health in the normal course of
39
40 care, specifically, by extracting comorbidities from linked governmental databases recording
41
42 community physician billings and hospital separations. Access and analysis of this
43
44 administrative data was performed by Alberta Health Services, the governmental data steward.
45
46 These data, and this linking process, have been widely used in other studies and have been
47
48 identified as valid.²²⁻²⁵ Most comorbidities were considered present if there were two
49
50 community visits with that diagnosis, or one hospital diagnosis, from any physician. However
51
52
53
54
55
56
57
58
59
60

1
2
3 only one such diagnosis was required for stroke (since the diagnosis might not repeat outside of
4 the acute event), and for chronic kidney disease (which, in our experience, is infrequently
5 recorded by primary care providers).
6
7
8
9

10 11 12 **Outcomes** (as self-reported by participants)

13 14 *Primary*

- 15
16 1. Adherence to bedtime allocation at 6-months (nonadherence = changing back to morning,
17 stopping altogether, or switching antihypertensives)
18
19

20 21 *Secondary*

- 22
23 1. Adherence to bedtime allocation at 6-weeks
24
25
- 26
27 2. Nocturia considered to be a “major burden” at 6-weeks, and at 6-months (includes those
28 who report a major burden, and those who failed the timing change because of nocturia)
29
30
- 31
32 3. Number of overnight urinations per week at 6-weeks, and at 6-months
33
34
35
36

37 38 **Statistical Analysis**

39
40 Our inclusion and exclusion criteria created one prospective cohort with two exposures, 1) an
41 established morning diuretic medication being switched to bedtime, and 2) an established
42 morning non-diuretic medication being switched to bedtime. Participants using a combination
43
44 morning non-diuretic medication being switched to bedtime. Participants using a combination
45
46 pill with two or more antihypertensive components were considered diuretic users if at least
47
48 one of those components was a diuretic. The analysis was by modified intention-to-treat and
49
50 consisted of descriptive statistics, comparing proportions using Fisher’s Exact Test (primary
51
52 outcome analysis), comparing the number of overnight urinations/week using Mann-Whitney,
53
54
55
56
57
58
59
60

1
2
3 and using Hodges-Lehmann estimation for difference in medians. All analyses utilized GraphPad
4
5 Prism version 9.1.2.
6
7
8
9

10 *Modified Intention-to-treat Assumptions*

- 13 1. Missing data: Missing variables were imputed using the value from the subsequent follow-
14
15 up interview. For example, if 6-week data were missing, adherence and nocturia burden
16
17 were assigned the 6-month value. If no subsequent data were available for imputation (i.e.,
18
19 loss to follow-up or study drop-out) participants were excluded from analysis. We did not
20
21 impute missing values for lost or dropped-out participants because we were looking to
22
23 demonstrate potential harm (harm constituting a difference in nonadherence or major
24
25 nocturia burden) and imputing missing values, being reasonably balanced between groups,
26
27 would have biased the groups towards looking more similar. Baseline characteristics of
28
29 those excluded from the primary analysis were compared to assess whether analysis
30
31 exclusion appeared random.
32
33
34
35
36
- 37 2. Medication changes: If nocturia resulted in participants switching medications, or
38
39 medication timing, we considered them non-adherent and to have a “major nocturia
40
41 burden”, even if a lesser degree of nocturia burden was reported at their follow-up
42
43 interview. Data from these non-adherent individuals was not used for assessment of
44
45 nocturia frequency. If medication or timing changes were made for reasons other than
46
47 nocturia, participants were excluded from analysis. We made this exclusion because
48
49 including such individuals would have biased the groups towards appearing more similar,
50
51 and could have led us to underestimate the nocturia burden in diuretic users. If physicians
52
53
54
55
56
57
58
59
60

1
2
3 changed the participant's medication to twice daily (with the second dose at bedtime or
4
5 dinnertime) we considered them to still experience the effects of a bedtime dose, and
6
7 included them in the analysis.
8
9

10 11 12 13 14 **Patient and Public Involvement**

15 16 *Patient working group*

17
18
19 BedMed has a 10-member patient working group which began meeting in 2016 prior to the
20
21 recruitment of any participants. Working group members have participated in 1) the
22
23 construction of all participant facing materials, 2) the wording of research assistant follow-up
24
25 scripts, 3) decisions as to what data to collect, and 3) the hiring of research assistants.
26
27
28

29 30 *Patient-driven question*

31
32
33 The draft BedMed protocol was presented to a group of ~25 seniors in 2015, prior to grant
34
35 application and study registration. The question pursued in this manuscript derived directly
36
37 from this group's feedback, where concern was expressed that bedtime diuretics would be
38
39 poorly tolerated due to nocturia.
40
41
42
43
44
45
46

47 **RESULTS**

48
49
50 Of 579 eligible participants, 552 (95.3%) had analyzable data at 6-weeks, and 533 (92.1%) had
51
52 analyzable data at 6-months. This included, for our 6-month adherence primary outcome,
53
54 198/210 (94.3%) of the eligible diuretic users and 335/369 (90.8%) of the eligible non-diuretic
55
56
57

1
2
3 users. Individual reasons for exclusion are shown in Figure 1. A comparison of baseline
4
5 characteristics (eTable 1 of the online supplement), shows no notable differences between
6
7 those excluded from the primary outcome analysis, and those analyzed. At 6-months, of those
8
9 considered compliant with allocation in the diuretic group, 147/153 (96.1%) took their
10
11 medication at bedtime, 5/153 (3.3%) took it at dinner, and 1/153 (0.7%) had their diuretic split
12
13 into twice daily dosing. This compares to the non-diuretic group, of whom 282/301 (93.7%)
14
15 took their medication at bedtime, 12/301 (4.0%) took it at dinner, and 7/301 (2.3%) had been
16
17 split into twice daily dosing.
18
19
20
21
22

23 *Baseline*

24
25 Overall, most participants were from Alberta (83.0%), 94.7% identified as white, and they were
26
27 a mean 65.6 (STD 10.0) years of age. Baseline characteristics were comparable between groups
28
29 (Table 1) although slightly more diuretic users were female (65.5% vs 52.7%). They were largely
30
31 non-smokers (92.4%), exercised a median 3 (IQR 0-5) days/week, and had a median BMI of 28.3
32
33 (IQR 25.5-32.3). The most common comorbidities were coronary artery disease (19.2%), sleep
34
35 apnea (18.3%), and diabetes (17.2%). The cohort-defining medications used are broken down in
36
37 Figure 2. Of the diuretic users, 142 (70.0%) used a thiazide containing combination pill, and 42
38
39 (20.7%) used hydrochlorothiazide alone. Although BedMed does not collect information on
40
41 drug dosage, it would be unusual for Canadians to be prescribed hydrochlorothiazide outside a
42
43 range of 12.5 – 25 mg/day. Of the non-diuretic cohort, 150 (43.0%) used angiotensin receptor
44
45 blockers (ARB), 148 (42.4%) used angiotensin-converting enzyme inhibitors (ACEI), 38 (10.9%)
46
47 used calcium channel blockers (CCB), 4 (1.1%) used beta-blockers (BB), and 9 (2.6%) used
48
49 combination pills that did not include diuretics. Baseline nocturia was similar between diuretic
50
51
52
53
54
55
56
57
58
59
60

vs non-diuretic users, in terms of the number of overnight urinations per week (median 5.5 vs 6.0), and the percentage of participants perceiving nocturia to be a major burden (1.5% vs 2.3%). However slightly more diuretic users felt nocturia was a minor burden (30.5% vs 23.5%). Overall, 3/4 of participants did experience nocturia at least once per week. Of these, 62.8% considered it “not a problem”, 34.5% considered it “a minor problem”, and 2.6% considered it “a major problem”.

Table 1. Baseline Characteristics

Characteristics	Diuretic (n=203) No. (%)	Non-Diuretic (n=349) No. (%)	p-value
Sex, female	133 (65.5)	184 (52.7)	0.004
Age, mean (STD), y	65.4 (8.9)	65.6 (10.6)	0.81
Province			
Alberta	169 (83.3)	289 (82.8)	0.99
British Columbia	14 (6.9)	37 (10.6)	0.17
Manitoba	16 (7.9)	19 (5.4)	0.23
Saskatchewan	4 (2.0)	4 (1.1)	0.47
Ethnicity			
White	195 (96.1)	328 (94.0)	0.33
South east asian	2 (1.0)	10 (2.9)	0.23
Asian	0	3 (0.8)	0.30
First nation	0	6 (1.7)	0.09
Black	0	0	0.99
Other	5 (2.5)	2 (0.6)	0.11
Decline to answer	1 (0.5)	0	0.37
Comorbidities ^a			
Coronary artery disease	39 (19.2)	67 (19.2)	0.99
Diabetes	31 (15.3)	64 (18.3)	0.41
Sleep apnea	38 (18.7)	63 (18.1)	0.91
Chronic kidney disease	14 (6.9)	39 (11.2)	0.13

COPD	16 (7.9)	35 (10.0)	0.45
Stroke	11 (5.4)	18 (5.2)	0.99
Heart failure	4 (2.0)	6 (1.7)	0.99
Cigarette smoker (current)	14 (6.9)	28 (8.0)	0.74
Physical exercise, median (IQR), days per week ^b	3 (1-5)	3 (0-5)	0.14
BMI, median (IQR), Kg/M ²	28.9 (26-33)	28.0 (25-32)	0.15
Underweight (< 18.5)	1 (0.5)	2 (0.6)	0.99
Normal weight (18.5 - 24.9)	35 (17.2)	74 (21.2)	0.27
Overweight (25 - 29.9)	84 (41.4)	143 (41.0)	0.93
Obese (≥ 30)	83 (40.9)	130 (37.2)	0.42
Nocturia, median (IQR), nocturnal urinations/wk	5.5 (1-10.5)	6.0 (1-10.5)	0.91
Does not experience nocturia	49 (24.1)	86 (24.6)	0.92
Nocturia occurs but "not a problem"	89 (43.8)	173 (49.6)	0.22
Nocturia "a minor problem"	62 (30.5)	82 (23.5)	0.07
Nocturia "a major problem"	3 (1.5)	8 (2.3)	0.75

^a Derived from Alberta provincial health claims data for 454 participants, and self-reported for 98.

^b "How many days in the past week have you exercised for 30 minutes or more, vigorously enough to raise your breathing rate?"

6-Weeks

Adherence with bedtime medication use was lower in diuretic users (88.7% vs 94.6%), but still high in both cohorts [difference 5.8%; 95%CI, 1.0% to 11.6%; p = 0.02; NNH 17.0] (Table 2).

Change in the number of overnight urinations per week could be calculated for 180 diuretic users, and 330 non-diuretic users (Figure 3). Compared to baseline, there were a median 1.0 more overnight urinations per week in diuretic users [95%CI, 0.0 to 1.5; p < 0.0001], and 9.9% more diuretic users perceived nocturia to be a major burden as compared with those who did not use diuretics [11.3% vs 1.4%; 95%CI Diff, 5.5% to 15.4%; p < 0.0001; Number Needed to Harm (NNH) 10.1] (Table 3).

6-Months

At 6-month, adherence to bedtime medication use (our primary outcome) had fallen somewhat in both groups (77.3% vs 89.8%), and the difference in adherence had widened [difference 12.6%; 95%CI Diff, 5.8% to 19.8%; $p < 0.0001$; NNH 8.0]. However most diuretic users were still adherent to bedtime medication use. Nocturia was given as the reason for nonadherence by 25/45 (55.6%) diuretic users, compared to 0/34 (0%) non-diuretic users, whose main reasons for nonadherence were forgetting to take their pill (10/34, 29.4%), worsening of BP control (8/34, 23.5%), and non-symptom driven medication changes (6/34, 17.6%). Of those still adherent to allocation (153 diuretic users and 301 non-diuretic users), the median difference in overnight urinations compared to baseline remained 1.0 urinations per week higher in diuretic users, compared to non-diuretic users [95%CI, 0.0 to 1.75; $p=0.012$]. Including those who had stopped adhering because of nocturia, 14.2% more diuretic users had perceived nocturia to be a major burden [15.6% vs 1.3%; 95%CI Diff, 8.9% to 20.6%; $p < 0.0001$; NNH 7.0].

Sex Differences

Given slightly more diuretic users were female, we conducted a post-hoc analysis to determine whether nocturia burden or adherence differed between sexes. Using the Mann-Whitney test there was no difference, male vs female, in the number of overnight urinations at 6-weeks for the diuretic group [median difference 0.0; 95%CI Diff, -1.0 to 1.0; $p = 0.96$], nor for the non-diuretic group [median difference 0.0; 95%CI Diff, 0.0 to 0.0; $p = 0.98$]. Adherence with bedtime antihypertensive use, diuretic vs non-diuretic users, was also similar between males and females at 6-months [male: 76.5% vs 90.5%; female: 77.7% vs 89.3%; $p = 0.86$ for the difference

in adherence between male and female diuretic users]. The same was true for major nocturia burden at 6-months, which was no different between sexes [male: 14.8% vs 0%; female: 16.0% vs 2.5%; $p > 0.99$ for the difference in major nocturia burden between male and female diuretic users].

Table 2. Non-adherence to Bedtime Allocation and Major Nocturia Burden, No. (%)

	Diuretic	Non-diuretic	Attributable Risk ^c (%) (95%CI)	p-value
6-weeks				
Major burden ^a	23/198 (11.6)	5/330 (1.5)	10.1 (5.6-15.7)	<0.0001
Nonadherence ^b	23/203 (11.3)	19/349 (5.4)	5.9 (1.0-11.6)	0.02
6-months				
Major burden ^a	28/180 (15.6)	4/301 (1.3)	14.2 (8.9-20.6)	<0.0001
Nonadherence ^b	45/198 (22.7)	34/335 (10.2)	12.6 (5.8-19.8)	<0.0001

^aIncludes those reporting major burden while using a bedtime diuretic, and those nonadherent due to nocturia. Data are number (%).

^bNonadherent for any reason. Data are number (%)

^cExcess risk of the outcome (noncompliance or major burden) for those in the diuretic group, compared to the non-diuretic group.

Table 3. Change in Number of Overnight Urinations per Week, median (IQR)

	Number of Overnight Urinations per Week		Median Change from Baseline		Between Group Difference Median (95%CI)	p-value
	Diuretic	Non-diuretic	Diuretic	Non-diuretic		
Baseline	5.5 (1.0-10.5)	6.0 (1.0-10.5)	-	-	0.0 ^{a,b} (0.0-0.0)	0.92
6-weeks	7.0 (2.6-11.6)	7.0 (1.5-10.5)	0.0 (0.0-3.5)	0.0 (-1.0-1.0)	1.0 ^{a,c} (0.0-1.5)	<0.0001
6-months	6.2 (0.0-10.5)	5.0 (0.0-10.5)	0.5 (-1.5-4.0)	0.0 (-2.0-2.0)	1.0 ^{a,d} (0.0-1.8)	0.01

^a The between group difference in medians is by Hodges–Lehmann estimation, hence this value differs from a simple subtraction of the diuretic and non-diuretic group medians provided

^b Between group difference for the median number of urinations per week at baseline

^c Between group difference for the median change from baseline at 6-weeks

^d Between group difference for the median change from baseline at 6-months

DISCUSSION

In this prospective cohort of hypertensive primary care patients, 1.5% of morning diuretic users experienced nocturia as a major burden at baseline. When these morning diuretic users switched their diuretic to bedtime, nocturia was more frequent, becoming a major burden for 15.6% of participants over a period of 6 months. Similar primary care patients simultaneously switching other types of antihypertensives from morning to bedtime experienced no increase in nocturia, but they still failed to adhere to bedtime use 10.2% of the time. Due to the extra burden of nocturia, nonadherence in diuretic users was higher, at 22.7%. Hence 1 in 8 diuretic users, compared to non-diuretic users, will fail the switch to bedtime, with 1 in 4 diuretic users failing the switch overall.

Our findings are limited by the potential for selection bias, given some BedMed participants may have previously tried diuretics (morning or evening) and, if they experienced troublesome nocturia, may have stopped using diuretics altogether prior to enrolling. Morning diuretic users may also have avoided enrolling in BedMed if they were concerned about the possibility of needing to switch their diuretics to bedtime. The subjective nature of our outcomes might also be considered a limitation, in that nocturia burden could be interpreted differently by different people. However, self-reporting of nocturia burden integrates the patient's perceptions and values, and our use of it prioritizes the individual's own assessment of their experience. Similarly, while our allowing patients struggling with bedtime use to switch their diuretic to dinnertime might lessen nocturia, this would likely reflect real world practice. Our findings are simultaneously strengthened by the prospective nature of the design, and by the cohort selection process, which ensured diuretic and non-diuretic users were all recruited

1
2
3 from the same practices, using the same approach, and meeting the same inclusion and
4
5 exclusion criteria.
6
7

8 To our knowledge, our study is the first to prospectively evaluate the link between
9
10 bedtime diuretic use and nocturia. Our finding the majority of diuretic users able to adhere to
11
12 bedtime use is consistent with the generally weak and variable association of diuretics and
13
14 nocturia in cross-sectional studies,^{11, 13} the inability of baseline diuretics to predict future
15
16 nocturia (2-year incidence) in 1,289 community dwelling MESA study respondents 60 years and
17
18 older,²⁶ and the number of participants changing the timing of a diuretic in the TIME
19
20 antihypertensive timing trial.²⁷ While 22.5% of TIME subjects used a diuretic at baseline, post-
21
22 randomization diuretic timing changes were made by 5.2% of the evening group vs 0.7% of the
23
24 morning group ($p < 0.0001$), suggesting $5.2\% / 22.5\% = \frac{1}{4}$ of diuretic users chose not to continue
25
26 bedtime use. Although bedtime antihypertensive use might offer an advantage so far as
27
28 cardiovascular risk reduction,^{4, 5} our clinical experience is that most BP-lowering medication is
29
30 still administered in the morning. In a 2017 survey of hypertensive primary care patients (single
31
32 center in Ohio, 139 respondents), 75.5% used all of their antihypertensive medication in the
33
34 morning.²⁸ Of the same population, 21 of 22 thiazide-diuretic users (95.5%) took that thiazide in
35
36 the morning.
37
38
39
40
41
42
43

44 Although roughly 14% of hypertensive primary care patients will newly experience
45
46 nocturia as a major burden after switching a thiazide diuretic from morning to bedtime, the
47
48 vast majority of morning diuretic users can successfully make the switch to bedtime should it
49
50 become clinically indicated to do so. The key remaining question is whether or not an attempt
51
52 to switch diuretics to bedtime is clinically indicated for cardiovascular risk reduction, as the
53
54
55
56
57
58
59
60

1
2
3 MAPEC and Hygia trials suggest.^{4, 5} Three confirmatory trials, of which BedMed is one, are
4
5 looking to evaluate this,^{15, 27, 29} with the first of these, the TIME trial,²⁷ recently reporting
6
7 neither benefit, nor harm, to bedtime prescribing. Final results of the remaining two trials,
8
9 BedMed,¹⁵ and BedMed-Frail,²⁹ are expected in mid 2024.
10
11
12
13
14

15 CONTRIBUTORS

16
17
18 SRG conceptualized the study. SRG, TK, MRK, GMA, JAB, AGS, AK, FAM, RSP, RL, MDH, KM,
19
20 DPM, STW, JPM, LAG designed the study and obtained grant funding. SRG, TK, MRK, GMA, AGS,
21
22 BGON, MG, DPM, DAM, JEMK, JPMA recruited physicians for the study. SRG supervised the
23
24 conduct of the trial. MDK and JMSY prepared the study data. SRG and MDK analyzed the data.
25
26 SRG and MDK wrote the draft manuscript. All authors contributed to critical revision of the
27
28 manuscript, and all authors approved the final manuscript. SRG is the guarantor. The
29
30 corresponding author attests that all listed authors meet authorship criteria and that no others
31
32 meeting the criteria have been omitted.
33
34
35
36
37
38
39

40 COMPETING INTERESTS

41
42
43 All authors have completed the ICMJE uniform disclosure form at
44
45 <https://www.icmje.org/disclosure-of-interest/> and declare: SRG is the nominated principal
46
47 applicant of two grants from governmental sources that are funding the BedMed trial (from
48
49 Alberta Innovates, and the Canadian Institutes of Health Research); RSP is CEO of “mmHg Inc”,
50
51 a digital health company and maker of software solutions for BP monitoring; MDH is the
52
53 recipient of several grants from pharmaceutical and device companies related to interventions
54
55
56
57
58
59
60

1
2
3 geared at stroke treatment. He holds two device patents related to stroke imaging, has chaired
4
5 or sat on the Data Safety Monitoring Boards of 5 other cardiovascular trials, is the President of
6
7 the Canadian Neurological Sciences Federation, a member of the board of the Canadian Stroke
8
9 Consortium, and has private stock ownership in two companies targeting imaging interventions
10
11 (Circle Inc, and PureWeb Inc).
12
13
14
15

16 17 18 FUNDING

19
20 BedMed is funded by a Support for Patient Oriented Research (SPOR) Innovative Clinical Trial
21
22 Multi-Year Grant (REF#: 151212) from the Canadian Institutes of Health Research (CIHR), and
23
24 from a Partnership for Research and Innovation in the Health System (PRIHS) Grant from
25
26 Alberta Innovates (REF#: 201 500 912 G2019000450). It also received in-kind research
27
28 assistance from Enhancing Alberta Primary Care Research Networks (EnACT), which itself is
29
30 funded entirely by Alberta Innovates, and received pilot funding from the Northern Alberta
31
32 Family Medicine Fund (University of Alberta Dept of Family Medicine funding).
33
34
35
36
37
38
39

40 41 DATA SHARING

42
43 Coincident with publication, de-identified patient-level data upon which this manuscript's
44
45 analyses are based will be freely available for download on the Pragmatic Trials Collaborative's
46
47 website (www.PragmaticTrials.ca).³⁰ Downloadable data will include age at study entry, sex,
48
49 specific BP medication used, corresponding cohort assignment (i.e. diuretic / non-diuretic),
50
51 baseline nocturia measures, and all primary and secondary outcomes.
52
53
54
55
56
57
58
59
60

ETHICAL APPROVAL

All procedures and methods were approved by the clinical research ethics boards of the Universities of Alberta (Pro00045958), Calgary (REB17-1887), British Columbia (H21-00523), Saskatchewan (1421), and Manitoba (HS20852:B2017:08).

COPYRIGHT/LICENCE FOR PUBLICATION

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

References

1. Turgeon RD, Althouse AD, Cohen JB, Enache B, Hogenesch JB, Johansen ME, et al. Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: Controversies in hypertension - con side of the argument. *Hypertension*. 2021;78:871-878
2. Kreutz R, Kjeldsen SE, Burnier M, Narkiewicz K, Oparil S, Mancia G. Disregard the reported data from the hygia project: Blood pressure medication not to be routinely dosed at bedtime. *J Hypertens*. 2020;38:2144-2145

3. Carlsberg B, Brunstrom B. Is bedtime the best time of day? *International Society of Hypertension March 2020 Newsletter* <https://ish-world.com/data/uploads/2003-1.pdf#page=19> Accessed Dec 17 2021
4. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the mapec study. *Chronobiol Int.* 2010;27:1629-1651
5. Hermida RC, Crespo JJ, Dominguez-Sardina M, Otero A, Moya A, Rios MT, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: The hygia chronotherapy trial. *European heart journal.* 2020;41:4565-4576
6. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. *Can J Cardiol.* 2020;36:596-624
7. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. *Cochrane Database Syst Rev.* 2018;4:CD001841
8. WebMD. Diuretics (water pills) for high blood pressure <https://www.webmd.com/hypertension-high-blood-pressure/guide/diuretic-treatment-high-blood-pressure> Accessed Jul 1 2021
9. Heart and Stroke Foundation of Canada. Diuretics <https://www.heartandstroke.ca/heart-disease/treatments/medications/diuretics> Accessed Jul 1 2021
10. Bosch JL, Weiss JP. The prevalence and causes of nocturia. *J Urol.* 2010;184:440-446
11. Asplund R. Nocturia in relation to sleep, health, and medical treatment in the elderly. *BJU Int.* 2005;96 Suppl 1:15-21
12. Ali A, Snape J. Nocturia in older people: A review of causes, consequences, assessment and management. *Int J Clin Pract.* 2004;58:366-373
13. Rembratt A, Norgaard JP, Andersson KE. Nocturia and associated morbidity in a community-dwelling elderly population. *BJU Int.* 2003;92:726-730
14. Asplund R, Aberg H. Health of the elderly with regard to sleep and nocturnal micturition. *Scand J Prim Health Care.* 1992;10:98-104
15. Garrison SR, Kolber MR, Allan GM, Bakal J, Green L, Singer A, et al. Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (bedmed): Protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. *BMJ Open.* 2022;12:e059711
16. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (probe) study. A novel design for intervention trials. Prospective randomized open blinded end-point. *Blood Press.* 1992;1:113-119
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (redcap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform.* 2009;42:377-381
18. Grieshaber MC, Flammer J. Blood flow in glaucoma. *Curr Opin Ophthalmol.* 2005;16:79-83

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Hayreh SS. Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension. *Curr Opin Ophthalmol*. 1999;10:474-482
 20. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. *Am J Ophthalmol*. 1994;117:603-624
 21. Krasinska B, Karolczak-Kulesza M, Krasinski Z, Pawlaczyk-Gabriel K, Lopatka P, Gluszek J, et al. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. *Blood Press*. 2012;21:240-248
 22. Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, et al. Methods for identifying 30 chronic conditions: Application to administrative data. *BMC Med Inform Decis Mak*. 2015;15:31
 23. Roos LL, Gupta S, Soodeen RA, Jebamani L. Data quality in an information-rich environment: Canada as an example. *Can J Aging*. 2005;24 Suppl 1:153-170
 24. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. *Stroke; a journal of cerebral circulation*. 2005;36:1776-1781
 25. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in icd-9-cm and icd-10 administrative data. *Med Care*. 2005;43:1130-1139
 26. Johnson TM, 2nd, Sattin RW, Parmelee P, Fultz NH, Ouslander JG. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. *J Am Geriatr Soc*. 2005;53:1011-1016
 27. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the uk (time study): A prospective, randomised, open-label, blinded-endpoint clinical trial. *Lancet*. 2022;400:1417-1425
 28. Perry LA, Surowiec S M, Danso DA, Kerobo OI, Anugwom AA, Couvertier KP. Evaluation of administration time and adherence rates of morning vs. Bedtime dosing of antihypertensive medications. *Journal of Contemporary Pharmacy Practice*. 2019;66:11-16
 29. Garrison SR. Bedmed-frail: Does the potential benefit of bedtime antihypertensive prescribing extend to frail populations? *National Institutes of Health Clinical Trials Registry* <https://www.clinicaltrials.gov/ct2/show/NCT04054648/> Accessed March 16 2023
 - [Dataset] 30. Garrison SR, Kelmer MD, Korownyk T, Kolber MR, Allan GM, Bakal JA, Singer AG, Katz A, McAlister FA, Padwal RS, Lewanczuk R, Hill MD, McGrail K, O'Neill BG, Greiver M, Manca DP, Mangin DA, Wong ST, Kirkwood JEM, McCormack JP, Yeung JMS, Green LA. Data from: Tolerability of bedtime diuretics: A prospective cohort analysis *Pragmatic Trials Collaborative Website*. April 30, 2023. <https://www.PragmaticTrials.ca/>

FIGURE LEGENDS

Figure 1:

Figure 1 Study flow diagram for analysis of adherence

Figure 2:

Figure 2 Medication frequency at baseline. HCTZ = hydrochlorothiazide

Figure 3:

Figure 3 6-week change in overnight urinations per week. Figure is the change in the number of overnight urinations per week experienced by hypertensive primary care patients 6-weeks after being randomly allocated to switch their only blood pressure lowering pill from morning to bedtime. Grouped by those whose pill contained a diuretic (90.7% of which were thiazides), and those who used a different class of blood pressure lowering medication.




Figure 1 Study flow diagram for analysis of adherence

163x190mm (150 x 150 DPI)




Figure 2 Medication frequency at baseline. HCTZ = hydrochlorothiazide

154x200mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3 6-week change in overnight urinations per week. Figure is the change in the number of overnight urinations per week experienced by hypertensive primary care patients 6-weeks after being randomly allocated to switch their only blood pressure lowering pill from morning to bedtime. Grouped by those whose pill contained a diuretic (90.7% of which were thiazides), and those who used a different class of blood pressure lowering medication.

165x116mm (150 x 150 DPI)

Tolerability of Bedtime Diuretics: A Prospective Cohort Analysis (Supplementary Information)

eTable 1. Comparison of baseline characteristics for participants that were excluded vs. included in the primary outcome analysis

Characteristics	Excluded (n=46) No. (%)	Included (n=533) No. (%)	p-value
Sex, female	27 (58.7)	308 (57.8)	0.99
Province			
Alberta	39 (84.8)	442 (82.9)	0.84
British Columbia	4 (8.7)	48 (9.0)	0.99
Manitoba	2 (4.4)	35 (6.6)	0.76
Saskatchewan	1 (2.2)	8 (1.5)	0.53
Rural resident	4 (8.7)	71 (13.3)	0.49
Age, mean (STD), y	64.6 (10.6)	65.5 (10.0)	0.55
≤ 29	0	1 (0.2)	0.99
30 - 39	0	2 (0.4)	0.99
40 - 49	3 (6.5)	24 (4.5)	0.46
50 - 59	9 (19.6)	116 (21.8)	0.85
60 - 69	18 (39.1)	202 (37.9)	0.87
70 - 79	11 (23.9)	146 (27.4)	0.73
80 - 89	5 (10.9)	39 (7.3)	0.38
≥ 90	0	3 (0.6)	0.99
Ethnicity			
White	43 (93.5)	504 (94.6)	0.73
South east asian	0	12 (2.3)	0.61
Asian	1 (2.2)	3 (0.6)	0.28
First nation	0	6 (1.1)	0.99
Black	0	0	0.99
Other	1 (2.2)	7 (1.3)	0.49
Decline to answer	1 (2.2)	1 (0.2)	0.15

Education level			
Less than high school	4 (8.7)	21 (3.9)	0.13
High school diploma	19 (41.3)	147 (27.6)	0.06
Technical or trade college diploma	9 (19.6)	146 (27.4)	0.30
University degree	13 (28.3)	219 (41.1)	0.12
Decline to answer	1 (2.2)	0	0.08
Annual household income, CAD\$			
< 25,000	4 (8.7)	25 (4.7)	0.28
25,000 to 100,000	20 (43.5)	287 (53.8)	0.22
> 100,000	20 (43.5)	189 (35.5)	0.34
Decline to answer	2 (4.4)	32 (6.0)	0.99
Comorbidities ^a			
Coronary artery disease	9 (19.6)	100 (18.8)	0.85
Diabetes	6 (13)	92 (17.3)	0.54
Sleep apnea	11 (23.9)	99 (18.6)	0.43
Chronic kidney disease	7 (15.2)	48 (9.0)	0.19
COPD	6 (13.0)	50 (9.4)	0.43
Stroke	1 (2.2)	28 (5.3)	0.72
Heart failure	0	10 (1.9)	0.99
Hip fracture	1 (2.2)	2 (0.4)	0.22
Cigarette smoker (current)	2 (4.4)	42 (7.9)	0.56
Nocturia, median (IQR), nocturnal urinations/wk	7 (0-14.0)	6 (1-10.5)	0.61
Does not experience nocturia	12 (26.1)	129 (24.2)	0.72
Nocturia occurs but "not a problem"	21 (45.6)	255 (47.8)	0.88
Nocturia "a minor problem"	12 (26.1)	139 (26.1)	0.99
Nocturia "a major problem"	1 (2.2)	10 (1.9)	0.60
Physical exercise, median (IQR), days per week ^b	3 (0-5.0)	3 (0.5-5.0)	0.42
0	15 (32.6)	133 (25.0)	0.29
1	6 (13.0)	43 (8.1)	0.26
2	1 (2.2)	68 (12.8)	0.03
3	6 (13.0)	75 (14.1)	0.99
4	6 (13.0)	54 (10.1)	0.46
5	2 (4.4)	49 (9.2)	0.41

6	1 (2.2)	15 (2.8)	0.99
7	9 (19.6)	96 (18.0)	0.84
BMI, median (IQR), Kg/M ²	27.7 (26.1-33.4)	28.3 (25.5-32.3)	0.80
Underweight (< 18.5)	0	3 (0.6)	0.99
Normal weight (18.5 - 24.9)	9 (19.6)	105 (19.7)	0.99
Overweight (25 - 29.9)	21 (45.7)	220 (41.3)	0.64
Obese (≥ 30)	16 (34.8)	205 (38.5)	0.75
EQ-5D-5L overall health score, median (IQR) ^c	80 (75-90)	80 (75-90)	0.88
Physically frail ^d	7 (15.2)	73 (13.7)	0.82
Cognition ^e			
Normal	41 (89.1)	496 (93.1)	0.37
Questionable impairment	3 (6.5)	36 (6.8)	0.99
Impairment consistent with dementia	2 (4.4)	1 (0.2)	0.02

^a Derived from Alberta provincial health claims data and self-report.

^b "How many days in the past week have you exercised for 30 minutes or more, vigorously enough to raise your breathing rate?"

^c Self-rating of overall health on a scale of 0 (worst) to 100 (best).

^d As per Tilburg Frailty Indicator's physical sub-scale (sub-scale score ≥3 defines physically frail).

^e As per Short Blessed screening test score. Considered to be normal (0-4), questionable impairment (5-9), or impairment consistent with dementia (>9).

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6-13
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9-11
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	11-13
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	14-18
Outcome data	15*	Report numbers of outcome events or summary measures over time	16-18

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-18
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14, 17-18
10				
11				
12	Discussion			
13	Key results	18	Summarise key results with reference to study objectives	19
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19-20
15				
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	20
18				
19				
20	Generalisability	21	Discuss the generalisability (external validity) of the study results	19-20
21				
22	Other information			
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22
24				
25				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Tolerability of bedtime diuretics: A prospective cohort analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-068188.R2
Article Type:	Original research
Date Submitted by the Author:	04-May-2023
Complete List of Authors:	<p>Garrison, Scott; University of Alberta Faculty of Medicine & Dentistry, Family Medicine; University of Alberta, Pragmatic Trials Collaborative Kelmer, Michael; University of Alberta, Faculty of Nursing; University of Alberta, Pragmatic Trials Collaborative Korownyk, Tina ; University of Alberta Faculty of Medicine & Dentistry, Family Medicine; University of Alberta, Pragmatic Trials Collaborative Kolber, Michael; University of Alberta Faculty of Medicine & Dentistry, Family Medicine; University of Alberta, Pragmatic Trials Collaborative Allan, Gary; College of Family Physicians of Canada, Programs and Practice Support; University of Alberta, Pragmatic Trials Collaborative Bakal, Jeffrey; Alberta Health Services, Provincial Research Data Services Singer , Alexander; University of Manitoba, Family Medicine Katz, Alan; University of Manitoba, Community Health Sciences Mcalister, Finlay; University of Alberta Faculty of Medicine & Dentistry, Medicine Padwal, Raj S ; University of Alberta Faculty of Medicine & Dentistry, Medicine Lewanczuk, Richard; University of Alberta Faculty of Medicine & Dentistry, Medicine Hill, Michael; University of Calgary Cumming School of Medicine, Clinical Neurosciences McGrail, Kimberlyn; The University of British Columbia, School of Population and Public Health O'Neill, Braden; University of Toronto, Family and Community Medicine Greiver, Michelle; University of Toronto, Family and Community Medicine Manca, Donna; University of Alberta Faculty of Medicine & Dentistry, Family Medicine Mangin, Dee; McMaster University Faculty of Health Sciences, Family Medicine Wong, Sabrina T.; The University of British Columbia, School of Population and Public Health Kirkwood, Jessica; University of Alberta Faculty of Medicine & Dentistry, Family Medicine McCormack, James; The University of British Columbia, Faculty of Pharmaceutical Sciences Yeung, Jack; Alberta Health Services, Provincial Research Data Services Green, Lee ; University of Alberta Faculty of Medicine & Dentistry, Family Medicine</p>
Primary Subject	Cardiovascular medicine

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Heading	
Secondary Subject Heading:	Pharmacology and therapeutics, General practice / Family practice, Urology
Keywords:	Hypertension < CARDIOLOGY, CLINICAL PHARMACOLOGY, PRIMARY CARE, Cardiology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Tolerability of bedtime diuretics: A prospective cohort analysis

Scott R Garrison, Professor;^{1,2} Michael D Kelmer, student;^{1,2} Tina Korownyk, Professor;^{1,2} Michael R Kolber Professor;^{1,2} G Michael Allan, Professor;^{1,3} Jeffrey A Bakal, Program Director;⁴ Alexander G Singer, Associate Professor;⁵ Alan Katz, Professor;⁵ Finlay A McAlister, Professor;⁶ Raj S Padwal, Professor;⁶ Richard Lewanczuk, Professor;⁶ Michael D Hill, Professor;⁷ Kimberlyn McGrail, Professor;^{8,9} Braden G O'Neill, Assistant Professor;¹⁰ Michelle Greiver, Associate Professor;¹⁰ Donna P Manca, Professor;² Dee A Mangin, Professor;¹¹ Sabrina T Wong, Professor;^{9,12} Jessica EM Kirkwood, Assistant Professor;^{1,2} James P McCormack, Professor;¹³ Jack MS Yeung, Programmer;⁴ Lee A Green, Professor.^{1,2}

¹Pragmatic Trials Collaborative, University of Alberta, Edmonton, AB; ²Dept of Family Medicine, University of Alberta, Edmonton, AB; ³College of Family Physicians of Canada; ⁴Provincial Research Data Services, Alberta Health Services, Edmonton, AB; ⁵Dept of Family Medicine, University of Manitoba, Winnipeg, MB; ⁶Dept of Medicine, University of Alberta, Edmonton, AB; ⁷Cumming School of Medicine, University of Calgary, Calgary, AB; ⁸School of Population and Public Health, University of Alberta, Edmonton, AB; ⁹Centre for Health Services and Policy research, Vancouver, BC; ¹⁰Dept of Family and Community Medicine, University of Toronto, Toronto, ON; ¹¹McMaster University, Hamilton, ON; ¹²School of Nursing, University of British Columbia, Vancouver, BC; ¹³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC

Corresponding Author:

Scott R Garrison MD, PhD, CCFP; 6-60 University Terrace, University of Alberta, Edmonton, Alberta, Canada, T6G 2T4; Phone: 587-785-3012; Email: scott.garrison@ualberta.ca

Co-authors:

Michael Kelmer kelmer@ualberta.ca
 Tina Korownyk cpoag@ualberta.ca
 Michael Kolber mkolber@ualberta.ca
 G Michael Allan mgallan@ualberta.ca
 Jeffrey Bakal jbakal@ualberta.ca
 Alex Singer alexandersinger@gmail.com
 Alan Katz Alan_Katz@cpe.umanitoba.ca
 Finlay McAlister finlay.mcalister@ualberta.ca
 Raj Padwal rpadwal@ualberta.ca
 Richard Lewanczuk rlewancz@ualberta.ca
 Michael Hill michael.hill@ucalgary.ca
 Kimberlyn McGrail kim.mcgrail@ubc.ca

Braden O'Neill braden.oneill@gmail.com
 Michelle Greiver Michelle.Greiver@nygh.on.ca
 Donna Manca dpmanca@ualberta.ca
 Dee Mangin mangind@mcmaster.ca
 Sabrina Wong sabrina.wong@ubc.ca
 Jessica Kirkwood jek5@ualberta.ca
 James McCormack james.mccormack@ubc.ca
 Jack Yeung ManShun.Yeung@albertahealthservices.ca
 Lee Green lagreen@ualberta.ca

ABSTRACT

OBJECTIVES

We sought to validate, or refute, the common belief that bedtime diuretics are poorly tolerated due to nocturia.

DESIGN

Prespecified prospective cohort analysis embedded within the randomized BedMed trial, in which hypertensive participants are randomized to morning vs. bedtime antihypertensive administration.

SETTING

352 community family practices across 4 Canadian provinces between March 2017 and September 2020.

PARTICIPANTS

552 hypertensive patients (65.6 years old, 57.4% female) already established on a single once-daily morning antihypertensive and randomized to switch that antihypertensive to bedtime. Of these, 203 used diuretics (27.1% thiazide alone, 70.0% thiazide/non-diuretic combinations) and 349 used non-diuretics.

INTERVENTION

Switching the established antihypertensive from morning to bedtime, and comparing the experience of diuretic and non-diuretic users.

PRIMARY AND SECONDARY OUTCOME MEASURES

PRIMARY OUTCOME: Adherence to bedtime allocation time at 6-months (defined as the willingness to continue with bedtime use, not an assessment of missed doses). SECONDARY 6-

1
2
3 MONTH OUTCOMES: 1) Nocturia considered to be a major burden, 2) Increase in overnight
4 urinations/week. All outcomes were self-reported, and additionally collected at 6-weeks.
5
6

7 8 **RESULTS** 9

10 At 6-months: Adherence to bedtime allocation time was lower in diuretic users than non-
11 diuretic users [77.3% vs 89.8%; difference 12.6%; 95%CI 5.8% to 19.8%; $p < 0.0001$; NNH 8.0],
12 and more diuretic users considered nocturia a major burden [15.6% vs 1.3%; difference 14.2%;
13 95%CI 8.9% to 20.6%; $p < 0.0001$; NNH 7.0]. Compared to baseline, diuretic users experienced
14
15 1.0 more overnight urinations/week [95%CI 0.0 to 1.75; $p = 0.01$]. Results did not differ
16
17 between sexes.
18
19
20
21
22
23

24 25 **CONCLUSIONS** 26

27 Switching diuretics to bedtime did promote nocturia, but only 15.6% found nocturia a major
28 burden. At 6-months, 77.3% of diuretic users were adherent to bedtime dosing. Bedtime
29 diuretic use is viable for many hypertensive patients, should it ever become clinically indicated.
30
31
32
33
34

35 **TRIAL REGISTRATION** 36

37 NCT02990663
38
39

40 **Key Words:** Hypertension, diuretics, nocturia, chronotherapy, bedtime
41
42
43
44
45

46 **STRENGTHS AND LIMITATIONS OF THIS STUDY** 47

- 48
49 • Our study question arises directly from members of the public who participated in the
50 design of the BedMed trial.
51
52
53
54
55
56
57
58
59
60

- Intervention and comparison groups were randomly selected from the same clinical trial population.
- Our data represent the first prospective evaluation of the tolerability of bedtime diuretics.
- Limitation: Those who previously tried and failed morning diuretics due to nocturia would be absent from the diuretic cohort, which could bias towards better bedtime diuretic tolerance.

INTRODUCTION

Although consensus is lacking,¹⁻³ two randomized trials by the same principal investigator suggest large reductions in major adverse cardiovascular events occur if blood pressure medications are taken at bedtime, as compared to conventional morning use.^{4,5} This finding, however, may be difficult to implement for those using diuretics - common first-line therapeutics, with a unique and important role in volume control and natriuresis.^{6,7} This is because diuretics are widely believed to promote nocturia, and typically recommended for morning use only as a result.^{8,9}

Nocturia occurs in roughly 2/3 of men and women over the age of 70 years¹⁰ and is believed to disrupt sleep, impair quality of life, and increase the risk of nighttime falls and fractures.^{11,12} However, there are no randomized trials examining diuretic timing and adverse effects. The concern that bedtime diuretics could produce troublesome nocturia, being based

1
2
3 on opinion and observational data, could be incorrect. Morning diuretics (typically thiazides)
4
5 are generally well tolerated, and cross-sectional analysis of diuretic-using populations, without
6
7 accounting for administration time, does not support a strong association between diuretic use
8
9 and nocturia.^{13, 14} Whether clinicians can recommend diuretics for bedtime use is therefore
10
11 unclear.
12
13
14
15

16 To determine how well diuretics are tolerated at bedtime we conducted a pre-specified
17
18 prospective cohort study embedded within the ongoing BedMed trial. BedMed randomizes
19
20 Canadian primary care patients with hypertension to take their existing antihypertensive
21
22 medications either in the morning, or at bedtime, and examines mortality and morbidity
23
24 outcomes.¹⁵ Recruitment started in March 2017 and the trial is ongoing, with follow-up
25
26 continuing until late 2023. This paper examines those participants with a single morning
27
28 antihypertensive at baseline who were randomized to switch that antihypertensive to bedtime.
29
30 Our goal was to compare adherence with bedtime allocation, and self-reported nocturia
31
32 burden, between those switching a diuretic to bedtime, and those switching other types of
33
34 blood pressure lowering medication to bedtime. Note, our definition of adherence to allocation
35
36 time differs from the conventional notion. When we refer to adherence to bedtime allocation,
37
38 we are talking about the participant's *intention* to use their antihypertensive at bedtime. This
39
40 study is NOT evaluating the extent to which individual doses are missed. As such, we did not
41
42 compare bedtime diuretic use to morning diuretic use because morning medication use was
43
44 already well established for all participants. As we have defined it, we would expect virtually
45
46 everyone allocated to morning antihypertensives to be adherent to their administration time,
47
48 as a morning allocation meant no change of any kind was needed.
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Study Design and Sample Size

BedMed is an ongoing prospective, randomized, open, blinded-endpoint (PROBE)¹⁶ trial.

Recruitment is registry-like, with participating family physicians using their usual-care electronic medical records to identify their eligible patients, and then mailing those patients information about the study. Interested patients call the study team and, if eligible and consenting, are randomized to take all their regular blood pressure medication (as tolerated) either in the morning, or at bedtime. Participants received their allocation, using the REDCap¹⁷ server's central randomization module, directly from a research assistant with no prior clinical interactions, achieving irreversible, independent, and concealed allocation.

The prospective cohort study reported in this manuscript is a prespecified interim analysis of BedMed data, carried out as part of an adaptive trial design. The analysis was triggered upon the allocation to bedtime dosing of 203 participants whose only baseline antihypertensive included a morning diuretic (whether a diuretic only, or a diuretic/non-diuretic combination pill). If adherence with bedtime diuretic use had been poor, the BedMed trial's inclusion criteria would have been altered to exclude future such individuals from enrolling. This sample size gave a 90% chance of detecting a 20% relative reduction in adherence to bedtime allocation if 1) morning adherence was 75%, and 2) there were an equal number of participants switching a non-diuretic antihypertensive to bedtime with whom to compare.

Setting and Participants

In Canada's publicly funded healthcare system, residents are not billed directly for physician services, but medication costs are either paid for privately, or partially or completely covered by either employer-sponsored health insurance, or government subsidized programs (including coverage for seniors). The vast majority of Canadians have family physicians, who are normally the sole prescriber of their patient's hypertension medications.

BedMed recruitment began in March 2017, with the final participant included in this analysis enrolling in September 2020. Over this period, participants were being recruited by 352 family physicians (typical practice panel ~ 1,500 patients, with 20% hypertension prevalence amongst adults) in the Canadian provinces of Alberta, Manitoba, British Columbia, and Saskatchewan. Some BedMed participants (22% of those randomized) also learned about the study through social media, or other sources, and were enrolled with their family physician's consent, but without their family physician actively recruiting them. To be eligible for BedMed, participants needed to be community dwelling (including assisted living), and to have a physician diagnosis of hypertension for which they used one or more blood pressure-lowering medications. BedMed excluded anyone with a personal history of glaucoma because of an association between nocturnal hypotension and ischemic optic neuropathy in such individuals.¹⁸⁻²¹ For this sub-study we intentionally kept our eligibility criteria as broad as possible (including participants with potentially nocturia-modifying conditions like diabetes, sleep apnea, and congestive heart failure) so as to most closely resemble, and be generalizable to, a hypertensive primary care population.

1
2
3
4
5
6 For this sub-study, the following inclusion and exclusion criteria defined the study cohort.
7

8 *Inclusion Criteria*
9

- 10
11 1. Physician diagnosis of hypertension
12
13 2. Only one antihypertensive pill in use at baseline (combination antihypertensive pills
14
15 permitted)
16
17 3. That single baseline antihypertensive pill was used in the morning at baseline, and only
18
19 once a day
20
21
22 4. The participant was randomized to switch that morning antihypertensive pill to bedtime
23
24
25
26

27
28 *Exclusion Criteria*
29

- 30 1. Participant did not attempt a medication timing change*
31
32 2. Physician changed the type of antihypertensive prior to the timing change*
33
34

35 *We made both these exclusions since, for the diuretic group, including patients who were
36
37 not actually attempting to switch a diuretic to bedtime would have lessened any potential
38
39 nocturia, and biased the groups towards looking more similar. When looking at adverse
40
41 effects of an intervention, such a “modified intention-to-treat” analysis is the more
42
43 conservative analytic option, given a full intention-to-treat analysis, for the reason
44
45 described above, is more likely to underestimate nocturia-related problems.
46
47
48
49
50

51
52 **Procedures**
53

54 *Assistance Changing Antihypertensive Medication to Bedtime*
55
56
57
58
59
60

1
2
3 Participants had their choice of being assisted in making their timing change by their family
4
5 physician, who applied their own judgement as to how to make the change or, if they described
6
7 no heart disease, by the research assistant with whom they were dialoging. Exceptions included
8
9 those whose BP-lowering medication was Tiazac XC or Diltiazem XC (which have delayed-
10
11 release kinetics), and furosemide, isosorbide mononitrate/dinitrate, or alpha blockers
12
13 (medications whose timing decision may be more complicated). Such participants had their
14
15 family physician guide their timing change. Advice from research assistants was to delay the
16
17 next morning dose until bedtime, and to continue all future doses at bedtime. If bedtime use
18
19 proved problematic, and there was concern participants would switch back to morning,
20
21 switching to dinnertime was suggested. As a memory aid, participants were advised to place pill
22
23 bottles near objects they use when getting ready for bed (e.g., toothbrush, denture case, alarm
24
25 clock), or to use an AM/PM dosette. If medication type, dosage, or timing needed to be
26
27 changed, for any reason, those decisions were at the sole discretion of the prescribing
28
29 physician.
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Follow-up Interviews*

45 Baseline characteristics were collected directly from participants through telephone interview
46
47 prior to randomization. The first follow-up with a research assistant occurred by telephone 7-
48
49 days post timing change to encourage adhering to the timing change, and to troubleshoot
50
51 participant concerns. Another telephone follow-up took place at 6-weeks to obtain self-
52
53 reported adherence to bedtime antihypertensive use (“Are you taking your blood pressure
54
55
56
57
58
59
60

1
2
3 medication at bedtime?"; and if "no" - the reason for not doing so), and to assess nocturia.
4
5 Participants could report nocturia as "no", "minor", or "major" burden (subjective overall
6
7 assessment, no itemized criteria), and they were asked to quantify the number of overnight
8
9 urinations per week by estimating the number of nights they rose to urinate, and the number of
10
11 times per night they urinated on those evenings. The same follow-up questions were asked
12
13 again at 6-months, either by telephone or by e-mail questionnaire (participant's choice), and
14
15 again every 6-months thereafter.
16
17
18

19
20 Note: this study was not designed to explore whether or not individual medication
21
22 doses were missed, something which could be better assessed with electronic devices, or pill
23
24 counting. We were instead assessing each participant's willingness to persist with bedtime
25
26 antihypertensive use. As such, self-report more accurately reflects the patient feedback
27
28 prescribers could expect, were they to recommend diuretics be administered at bedtime.
29
30
31
32
33
34

35 *Administrative Health Claims Data*

36
37 Comorbidities were also collected as baseline characteristics (coronary artery disease, diabetes,
38
39 sleep apnea, chronic kidney disease, chronic obstructive pulmonary disease (COPD), congestive
40
41 heart failure (CHF), and stroke). For non-Alberta residents, these comorbidities were self-
42
43 reported. For Alberta residents, the vast majority of participants (83%), these comorbidities
44
45 were derived from physician diagnoses submitted to Alberta Health in the normal course of
46
47 care, specifically, by extracting comorbidities from linked governmental databases recording
48
49 community physician billings and hospital separations. Access and analysis of this
50
51 administrative data was performed by Alberta Health Services, the governmental data steward.
52
53
54
55
56
57
58
59
60

1
2
3 These data, and this linking process, have been widely used in other studies and have been
4
5 identified as valid.²²⁻²⁵ Most comorbidities were considered present if there were two
6
7 community visits with that diagnosis, or one hospital diagnosis, from any physician. However
8
9 only one such diagnosis was required for stroke (since the diagnosis might not repeat outside of
10
11 the acute event), and for chronic kidney disease (which, in our experience, is infrequently
12
13 recorded by primary care providers).
14
15
16
17
18
19

20 **Outcomes** (as self-reported by participants)

21 *Primary*

- 22 1. Adherence to bedtime allocation at 6-months (nonadherence = changing back to morning,
23
24 stopping altogether, or switching antihypertensives)
25
26
27
28

29 *Secondary*

- 30 1. Adherence to bedtime allocation at 6-weeks
31
32
- 33 2. Nocturia considered to be a “major burden” at 6-weeks, and at 6-months (includes those
34
35 who report a major burden, and those who failed the timing change because of nocturia)
36
37
38
- 39 3. Number of overnight urinations per week at 6-weeks, and at 6-months
40
41
42
43

44 **Statistical Analysis**

45
46
47 Our inclusion and exclusion criteria created one prospective cohort with two exposures, 1) an
48
49 established morning diuretic medication being switched to bedtime, and 2) an established
50
51 morning non-diuretic medication being switched to bedtime. Participants using a combination
52
53 pill with two or more antihypertensive components were considered diuretic users if at least
54
55
56
57
58
59
60

1
2
3 one of those components was a diuretic. The analysis was by modified intention-to-treat and
4
5 consisted of descriptive statistics, comparing proportions using Fisher's Exact Test (primary
6
7 outcome analysis), comparing the number of overnight urinations/week using Mann-Whitney,
8
9 and using Hodges-Lehmann estimation for difference in medians. All analyses utilized GraphPad
10
11 Prism version 9.1.2.
12
13
14
15
16
17

18 *Modified Intention-to-treat Assumptions*

- 19
20 1. Missing data: Missing variables were imputed using the value from the subsequent follow-
21
22 up interview. For example, if 6-week data were missing, adherence and nocturia burden
23
24 were assigned the 6-month value. If no subsequent data were available for imputation (i.e.,
25
26 loss to follow-up or study drop-out) participants were excluded from analysis. We did not
27
28 impute missing values for lost or dropped-out participants because we were looking to
29
30 demonstrate potential harm (harm constituting a difference in nonadherence or major
31
32 nocturia burden) and imputing missing values, being reasonably balanced between groups,
33
34 would have biased the groups towards looking more similar. Baseline characteristics of
35
36 those excluded from the primary analysis were compared to assess whether analysis
37
38 exclusion appeared random.
39
40
41
42
43
44
- 45 2. Medication changes: If nocturia resulted in participants switching medications, or
46
47 medication timing, we considered them non-adherent and to have a "major nocturia
48
49 burden", even if a lesser degree of nocturia burden was reported at their follow-up
50
51 interview. Data from these non-adherent individuals was not used for assessment of
52
53 nocturia frequency. If medication or timing changes were made for reasons other than
54
55
56
57
58
59
60

1
2
3 nocturia, participants were excluded from analysis. We made this exclusion because
4
5 including such individuals would have biased the groups towards appearing more similar,
6
7 and could have led us to underestimate the nocturia burden in diuretic users. If physicians
8
9 changed the participant's medication to twice daily (with the second dose at bedtime or
10
11 dinnertime) we considered them to still experience the effects of a bedtime dose, and
12
13 included them in the analysis.
14
15
16
17
18
19
20

21 **Patient and Public Involvement**

22 *Patient working group*

23
24
25
26
27 BedMed has a 10-member patient working group which began meeting in 2016 prior to the
28
29 recruitment of any participants. Working group members have participated in 1) the
30
31 construction of all participant facing materials, 2) the wording of research assistant follow-up
32
33 scripts, 3) decisions as to what data to collect, and 3) the hiring of research assistants.
34
35
36

37 *Patient-driven question*

38
39
40 The draft BedMed protocol was presented to a group of ~25 seniors in 2015, prior to grant
41
42 application and study registration. The question pursued in this manuscript derived directly
43
44 from this group's feedback, where concern was expressed that bedtime diuretics would be
45
46 poorly tolerated due to nocturia.
47
48
49
50
51
52
53

54 **RESULTS**

1
2
3 De-identified patient-level outcome data are available for download on the Pragmatic Trials
4 Collaborative's website (www.PragmaticTrials.ca).²⁶ Of 579 eligible participants, 552 (95.3%)
5
6 had analyzable data at 6-weeks, and 533 (92.1%) had analyzable data at 6-months. This
7
8 included, for our 6-month adherence primary outcome, 198/210 (94.3%) of the eligible diuretic
9
10 users and 335/369 (90.8%) of the eligible non-diuretic users. Individual reasons for exclusion
11
12 are shown in Figure 1. A comparison of baseline characteristics (Supplemental Table 1), shows
13
14 no notable differences between those excluded from the primary outcome analysis, and those
15
16 analyzed. At 6-months, of those considered compliant with allocation in the diuretic group,
17
18 147/153 (96.1%) took their medication at bedtime, 5/153 (3.3%) took it at dinner, and 1/153
19
20 (0.7%) had their diuretic split into twice daily dosing. This compares to the non-diuretic group,
21
22 of whom 282/301 (93.7%) took their medication at bedtime, 12/301 (4.0%) took it at dinner,
23
24 and 7/301 (2.3%) had been split into twice daily dosing.
25
26
27
28
29
30
31
32

33 *Baseline*

34
35
36 Overall, most participants were from Alberta (83.0%), 94.7% identified as white, and they were
37
38 a mean 65.6 (STD 10.0) years of age. Baseline characteristics were comparable between groups
39
40 (Table 1) although slightly more diuretic users were female (65.5% vs 52.7%). They were largely
41
42 non-smokers (92.4%), exercised a median 3 (IQR 0-5) days/week, and had a median BMI of 28.3
43
44 (IQR 25.5-32.3). The most common comorbidities were coronary artery disease (19.2%), sleep
45
46 apnea (18.3%), and diabetes (17.2%). The cohort-defining medications used are broken down in
47
48 Figure 2. Of the diuretic users, 142 (70.0%) used a thiazide containing combination pill, and 42
49
50 (20.7%) used hydrochlorothiazide alone. Although BedMed does not collect information on
51
52 drug dosage, it would be unusual for Canadians to be prescribed hydrochlorothiazide outside a
53
54
55
56
57
58
59
60

range of 12.5 – 25 mg/day. Of the non-diuretic cohort, 150 (43.0%) used angiotensin receptor blockers (ARB), 148 (42.4%) used angiotensin-converting enzyme inhibitors (ACEI), 38 (10.9%) used calcium channel blockers (CCB), 4 (1.1%) used beta-blockers (BB), and 9 (2.6%) used combination pills that did not include diuretics. Baseline nocturia was similar between diuretic vs non-diuretic users, in terms of the number of overnight urinations per week (median 5.5 vs 6.0), and the percentage of participants perceiving nocturia to be a major burden (1.5% vs 2.3%). However slightly more diuretic users felt nocturia was a minor burden (30.5% vs 23.5%). Overall, 3/4 of participants did experience nocturia at least once per week. Of these, 62.8% considered it “not a problem”, 34.5% considered it “a minor problem”, and 2.6% considered it “a major problem”.

Table 1. Baseline Characteristics

Characteristics	Diuretic (n=203) No. (%)	Non-Diuretic (n=349) No. (%)	p-value
Sex, female	133 (65.5)	184 (52.7)	0.004
Age, mean (STD), y	65.4 (8.9)	65.6 (10.6)	0.81
Province			
Alberta	169 (83.3)	289 (82.8)	0.99
British Columbia	14 (6.9)	37 (10.6)	0.17
Manitoba	16 (7.9)	19 (5.4)	0.23
Saskatchewan	4 (2.0)	4 (1.1)	0.47
Ethnicity			
White	195 (96.1)	328 (94.0)	0.33
South east asian	2 (1.0)	10 (2.9)	0.23
Asian	0	3 (0.8)	0.30
First nation	0	6 (1.7)	0.09
Black	0	0	0.99
Other	5 (2.5)	2 (0.6)	0.11

Decline to answer	1 (0.5)	0	0.37
Comorbidities^a			
Coronary artery disease	39 (19.2)	67 (19.2)	0.99
Diabetes	31 (15.3)	64 (18.3)	0.41
Sleep apnea	38 (18.7)	63 (18.1)	0.91
Chronic kidney disease	14 (6.9)	39 (11.2)	0.13
COPD	16 (7.9)	35 (10.0)	0.45
Stroke	11 (5.4)	18 (5.2)	0.99
Heart failure	4 (2.0)	6 (1.7)	0.99
Cigarette smoker (current)	14 (6.9)	28 (8.0)	0.74
Physical exercise, median (IQR), days per week ^b	3 (1-5)	3 (0-5)	0.14
BMI, median (IQR), Kg/M²			
Underweight (< 18.5)	1 (0.5)	2 (0.6)	0.99
Normal weight (18.5 - 24.9)	35 (17.2)	74 (21.2)	0.27
Overweight (25 - 29.9)	84 (41.4)	143 (41.0)	0.93
Obese (≥ 30)	83 (40.9)	130 (37.2)	0.42
Nocturia, median (IQR), nocturnal urinations/wk			
Does not experience nocturia	5.5 (1-10.5)	6.0 (1-10.5)	0.91
Nocturia occurs but "not a problem"	49 (24.1)	86 (24.6)	0.92
Nocturia "a minor problem"	89 (43.8)	173 (49.6)	0.22
Nocturia "a major problem"	62 (30.5)	82 (23.5)	0.07
Nocturia "a major problem"	3 (1.5)	8 (2.3)	0.75

^a Derived from Alberta provincial health claims data for 454 participants, and self-reported for 98.

^b "How many days in the past week have you exercised for 30 minutes or more, vigorously enough to raise your breathing rate?"

6-Weeks

Adherence with bedtime medication use was lower in diuretic users (88.7% vs 94.6%), but still high in both cohorts [difference 5.8%; 95%CI, 1.0% to 11.6%; p = 0.02; NNH 17.0] (Table 2).

Change in the number of overnight urinations per week could be calculated for 180 diuretic users, and 330 non-diuretic users (Supplemental Figure 1). Compared to baseline, there were a

1
2
3 median 1.0 more overnight urinations per week in diuretic users [95%CI, 0.0 to 1.5; $p < 0.0001$],
4
5 and 9.9% more diuretic users perceived nocturia to be a major burden as compared with those
6
7 who did not use diuretics [11.3% vs 1.4%; 95%CI Diff, 5.5% to 15.4%; $p < 0.0001$; Number
8
9 Needed to Harm (NNH) 10.1] (Table 3).
10
11

12 13 *6-Months*

14
15
16 At 6-month, adherence to bedtime medication use (our primary outcome) had fallen somewhat
17
18 in both groups (77.3% vs 89.8%), and the difference in adherence had widened [difference
19
20 12.6%; 95%CI Diff, 5.8% to 19.8%; $p < 0.0001$; NNH 8.0]. However most diuretic users were still
21
22 adherent to bedtime medication use. Nocturia was given as the reason for nonadherence by
23
24 25/45 (55.6%) diuretic users, compared to 0/34 (0%) non-diuretic users, whose main reasons
25
26 for nonadherence were forgetting to take their pill (10/34, 29.4%), worsening of BP control
27
28 (8/34, 23.5%), and non-symptom driven medication changes (6/34, 17.6%). Of those still
29
30 adherent to allocation (153 diuretic users and 301 non-diuretic users), the median difference in
31
32 overnight urinations compared to baseline remained 1.0 urinations per week higher in diuretic
33
34 users, compared to non-diuretic users [95%CI, 0.0 to 1.75; $p=0.012$]. Including those who had
35
36 stopped adhering because of nocturia, 14.2% more diuretic users had perceived nocturia to be
37
38 a major burden [15.6% vs 1.3%; 95%CI Diff, 8.9% to 20.6%; $p < 0.0001$; NNH 7.0].
39
40
41
42
43
44
45

46 47 *Sex Differences*

48
49 Given slightly more diuretic users were female, we conducted a post-hoc analysis to determine
50
51 whether nocturia burden or adherence differed between sexes. Using the Mann-Whitney test
52
53 there was no difference, male vs female, in the number of overnight urinations at 6-weeks for
54
55
56
57
58
59
60

the diuretic group [median difference 0.0; 95%CI Diff, -1.0 to 1.0; $p = 0.96$], nor for the non-diuretic group [median difference 0.0; 95%CI Diff, 0.0 to 0.0; $p = 0.98$]. Adherence with bedtime antihypertensive use, diuretic vs non-diuretic users, was also similar between males and females at 6-months [male: 76.5% vs 90.5%; female: 77.7% vs 89.3%; $p = 0.86$ for the difference in adherence between male and female diuretic users]. The same was true for major nocturia burden at 6-months, which was no different between sexes [male: 14.8% vs 0%; female: 16.0% vs 2.5%; $p > 0.99$ for the difference in major nocturia burden between male and female diuretic users].

Table 2. Non-adherence to Bedtime Allocation and Major Nocturia Burden, No. (%)

	Diuretic	Non-diuretic	Attributable Risk ^c (%) (95%CI)	p-value
6-weeks				
Major burden ^a	23/198 (11.6)	5/330 (1.5)	10.1 (5.6-15.7)	<0.0001
Nonadherence ^b	23/203 (11.3)	19/349 (5.4)	5.9 (1.0-11.6)	0.02
6-months				
Major burden ^a	28/180 (15.6)	4/301 (1.3)	14.2 (8.9-20.6)	<0.0001
Nonadherence ^b	45/198 (22.7)	34/335 (10.2)	12.6 (5.8-19.8)	<0.0001

^aIncludes those reporting major burden while using a bedtime diuretic, and those nonadherent due to nocturia. Data are number (%).

^bNonadherent for any reason. Data are number (%)

^cExcess risk of the outcome (noncompliance or major burden) for those in the diuretic group, compared to the non-diuretic group.

Table 3. Change in Number of Overnight Urinations per Week, median (IQR)

	Number of Overnight Urinations per Week		Median Change from Baseline		Between Group Difference Median (95%CI)	p-value
	Diuretic	Non-diuretic	Diuretic	Non-diuretic		
Baseline	5.5 (1.0-10.5)	6.0 (1.0-10.5)	-	-	0.0 ^{a,b} (0.0-0.0)	0.92
6-weeks	7.0 (2.6-11.6)	7.0 (1.5-10.5)	0.0 (0.0-3.5)	0.0 (-1.0-1.0)	1.0 ^{a,c} (0.0-1.5)	<0.0001
6-months	6.2 (0.0-10.5)	5.0 (0.0-10.5)	0.5 (-1.5-4.0)	0.0 (-2.0-2.0)	1.0 ^{a,d} (0.0-1.8)	0.01

^a The between group difference in medians is by Hodges–Lehmann estimation, hence this value differs from a simple subtraction of the diuretic and non-diuretic group medians provided

^b Between group difference for the median number of urinations per week at baseline

^c Between group difference for the median change from baseline at 6-weeks

^d Between group difference for the median change from baseline at 6-months

DISCUSSION

In this prospective cohort of hypertensive primary care patients, 1.5% of morning diuretic users experienced nocturia as a major burden at baseline. When these morning diuretic users switched their diuretic to bedtime, nocturia was more frequent, becoming a major burden for 15.6% of participants over a period of 6 months. Similar primary care patients simultaneously switching other types of antihypertensives from morning to bedtime experienced no increase in nocturia, but they still failed to adhere to bedtime use 10.2% of the time. Due to the extra burden of nocturia, nonadherence in diuretic users was higher, at 22.7%. Hence 1 in 8 diuretic users, compared to non-diuretic users, will fail the switch to bedtime, with 1 in 4 diuretic users failing the switch overall.

Our findings are limited by the potential for selection bias, given some BedMed participants may have previously tried diuretics (morning or evening) and, if they experienced troublesome nocturia, may have stopped using diuretics altogether prior to enrolling. Morning diuretic users may also have avoided enrolling in BedMed if they were concerned about the possibility of needing to switch their diuretics to bedtime. The subjective nature of our outcomes might also be considered a limitation, in that nocturia burden could be interpreted differently by different people. However, self-reporting of nocturia burden integrates the patient's perceptions and values, and our use of it prioritizes the individual's own assessment of

1
2
3 their experience. Similarly, while our allowing patients struggling with bedtime use to switch
4 their diuretic to dinnertime might lessen nocturia, this would likely reflect real world practice.
5
6 Our findings are simultaneously strengthened by the prospective nature of the design, and by
7
8 the cohort selection process, which ensured diuretic and non-diuretic users were all recruited
9
10 from the same practices, using the same approach, and meeting the same inclusion and
11
12 exclusion criteria.
13
14
15
16
17

18 To our knowledge, our study is the first to prospectively evaluate the link between
19
20 bedtime diuretic use and nocturia. Our finding the majority of diuretic users able to adhere to
21
22 bedtime use is consistent with the generally weak and variable association of diuretics and
23
24 nocturia in cross-sectional studies,^{11, 13} the inability of baseline diuretics to predict future
25
26 nocturia (2-year incidence) in 1,289 community dwelling MESA study respondents 60 years and
27
28 older,²⁷ and the number of participants changing the timing of a diuretic in the TIME
29
30 antihypertensive timing trial.²⁸ While 22.5% of TIME subjects used a diuretic at baseline, post-
31
32 randomization diuretic timing changes were made by 5.2% of the evening group vs 0.7% of the
33
34 morning group ($p < 0.0001$), suggesting $5.2\% / 22.5\% = \frac{1}{4}$ of diuretic users chose not to continue
35
36 bedtime use. Although bedtime antihypertensive use might offer an advantage so far as
37
38 cardiovascular risk reduction,^{4, 5} our clinical experience is that most BP-lowering medication is
39
40 still administered in the morning. In a 2017 survey of hypertensive primary care patients (single
41
42 center in Ohio, 139 respondents), 75.5% used all of their antihypertensive medication in the
43
44 morning.²⁹ Of the same population, 21 of 22 thiazide-diuretic users (95.5%) took that thiazide in
45
46 the morning.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Although roughly 14% of hypertensive primary care patients will newly experience
4
5 nocturia as a major burden after switching a thiazide diuretic from morning to bedtime, the
6
7 vast majority of morning diuretic users can successfully make the switch to bedtime should it
8
9 become clinically indicated to do so. The key remaining question is whether or not an attempt
10
11 to switch diuretics to bedtime is clinically indicated for cardiovascular risk reduction, as the
12
13 MAPEC and Hygia trials suggest.^{4, 5} Three confirmatory trials, of which BedMed is one, are
14
15 looking to evaluate this,^{15, 28, 30} with the first of these, the TIME trial,²⁸ recently reporting
16
17 neither benefit, nor harm, to bedtime prescribing. Final results of the remaining two trials,
18
19 BedMed,¹⁵ and BedMed-Frail,³⁰ are expected in mid 2024.
20
21
22
23
24
25
26
27

28 CONTRIBUTORS

29
30 SRG conceptualized the study. SRG, TK, MRK, GMA, JAB, AGS, AK, FAM, RSP, RL, MDH, KM,
31
32 DPM, STW, JPM, LAG designed the study and obtained grant funding. SRG, TK, MRK, GMA, AGS,
33
34 BGON, MG, DPM, DAM, JEMK, JPMA recruited physicians for the study. SRG supervised the
35
36 conduct of the trial. MDK and JMSY prepared the study data. SRG and MDK analyzed the data.
37
38 SRG and MDK wrote the draft manuscript. All authors contributed to critical revision of the
39
40 manuscript, and all authors approved the final manuscript. SRG is the guarantor. The
41
42 corresponding author attests that all listed authors meet authorship criteria and that no others
43
44 meeting the criteria have been omitted.
45
46
47
48
49
50
51

52 COMPETING INTERESTS

53
54
55
56
57
58
59
60

1
2
3 All authors have completed the ICMJE uniform disclosure form at
4
5 <https://www.icmje.org/disclosure-of-interest/> and declare: SRG is the nominated principal
6
7 applicant of two grants from governmental sources that are funding the BedMed trial (from
8
9 Alberta Innovates, and the Canadian Institutes of Health Research); RSP is CEO of “mmHg Inc”,
10
11 a digital health company and maker of software solutions for BP monitoring; MDH is the
12
13 recipient of several grants from pharmaceutical and device companies related to interventions
14
15 geared at stroke treatment. He holds two device patents related to stroke imaging, has chaired
16
17 or sat on the Data Safety Monitoring Boards of 5 other cardiovascular trials, is the President of
18
19 the Canadian Neurological Sciences Federation, a member of the board of the Canadian Stroke
20
21 Consortium, and has private stock ownership in two companies targeting imaging interventions
22
23 (Circle Inc, and PureWeb Inc).
24
25
26
27
28
29
30
31

32 FUNDING

33
34
35 BedMed is funded by a Support for Patient Oriented Research (SPOR) Innovative Clinical Trial
36
37 Multi-Year Grant (REF#: 151212) from the Canadian Institutes of Health Research (CIHR), and
38
39 from a Partnership for Research and Innovation in the Health System (PRIHS) Grant from
40
41 Alberta Innovates (REF#: 201 500 912 G2019000450). It also received in-kind research
42
43 assistance from Enhancing Alberta Primary Care Research Networks (EnACT), which itself is
44
45 funded entirely by Alberta Innovates, and received pilot funding from the Northern Alberta
46
47 Family Medicine Fund (University of Alberta Dept of Family Medicine funding).
48
49
50
51
52
53
54

55 DATA SHARING

1
2
3 Coincident with publication, de-identified patient-level data upon which this manuscript's
4
5 analyses are based will be freely available for download on the Pragmatic Trials Collaborative's
6
7 website (www.PragmaticTrials.ca). Downloadable data will include age at study entry, sex,
8
9 specific BP medication used, corresponding cohort assignment (i.e. diuretic / non-diuretic),
10
11 baseline nocturia measures, and all primary and secondary outcomes.
12
13
14
15

16 17 18 ETHICAL APPROVAL

19
20 All procedures and methods were approved by the clinical research ethics boards of the
21
22 Universities of Alberta (Pro00045958), Calgary (REB17-1887), British Columbia (H21-00523),
23
24 Saskatchewan (1421), and Manitoba (HS20852:B2017:08).
25
26
27
28
29

30 31 COPYRIGHT/LICENCE FOR PUBLICATION

32
33 The Corresponding Author has the right to grant on behalf of all authors and does grant on
34
35 behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all
36
37 forms, formats and media (whether known now or created in the future), to i) publish,
38
39 reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
40
41 other languages, create adaptations, reprints, include within collections and create summaries,
42
43 extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on
44
45 the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of
46
47 electronic links from the Contribution to third party material where-ever it may be located; and,
48
49
50
51
52
53 vi) licence any third party to do any or all of the above.
54
55
56
57
58
59
60

References

1. Turgeon RD, Althouse AD, Cohen JB, Enache B, Hogenesch JB, Johansen ME, et al. Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: Controversies in hypertension - con side of the argument. *Hypertension*. 2021;78:871-878
2. Kreutz R, Kjeldsen SE, Burnier M, Narkiewicz K, Oparil S, Mancia G. Disregard the reported data from the hygia project: Blood pressure medication not to be routinely dosed at bedtime. *J Hypertens*. 2020;38:2144-2145
3. Carlsberg B, Brunstrom B. Is bedtime the best time of day? *International Society of Hypertension March 2020 Newsletter* <https://ish-world.com/data/uploads/2003-1.pdf#page=19> Accessed Dec 17 2021
4. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of circadian time of hypertension treatment on cardiovascular risk: Results of the mapec study. *Chronobiol Int*. 2010;27:1629-1651
5. Hermida RC, Crespo JJ, Dominguez-Sardina M, Otero A, Moya A, Rios MT, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: The hygia chronotherapy trial. *European heart journal*. 2020;41:4565-4576
6. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. *Can J Cardiol*. 2020;36:596-624
7. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. *Cochrane Database Syst Rev*. 2018;4:CD001841
8. WebMD. Diuretics (water pills) for high blood pressure <https://www.webmd.com/hypertension-high-blood-pressure/guide/diuretic-treatment-high-blood-pressure> Accessed Jul 1 2021
9. Heart and Stroke Foundation of Canada. Diuretics <https://www.heartandstroke.ca/heart-disease/treatments/medications/diuretics> Accessed Jul 1 2021
10. Bosch JL, Weiss JP. The prevalence and causes of nocturia. *J Urol*. 2010;184:440-446
11. Asplund R. Nocturia in relation to sleep, health, and medical treatment in the elderly. *BJU Int*. 2005;96 Suppl 1:15-21
12. Ali A, Snape J. Nocturia in older people: A review of causes, consequences, assessment and management. *Int J Clin Pract*. 2004;58:366-373
13. Rembratt A, Norgaard JP, Andersson KE. Nocturia and associated morbidity in a community-dwelling elderly population. *BJU Int*. 2003;92:726-730
14. Asplund R, Aberg H. Health of the elderly with regard to sleep and nocturnal micturition. *Scand J Prim Health Care*. 1992;10:98-104
15. Garrison SR, Kolber MR, Allan GM, Bakal J, Green L, Singer A, et al. Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (bedmed): Protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. *BMJ Open*. 2022;12:e059711

16. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (probe) study. A novel design for intervention trials. Prospective randomized open blinded end-point. *Blood Press*. 1992;1:113-119
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (redcap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377-381
18. Grieshaber MC, Flammer J. Blood flow in glaucoma. *Curr Opin Ophthalmol*. 2005;16:79-83
19. Hayreh SS. Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension. *Curr Opin Ophthalmol*. 1999;10:474-482
20. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. *Am J Ophthalmol*. 1994;117:603-624
21. Krasinska B, Karolczak-Kulesza M, Krasinski Z, Pawlaczyk-Gabriel K, Lopatka P, Gluszek J, et al. Effects of the time of antihypertensive drugs administration on the stage of primary open-angle glaucoma in patients with arterial hypertension. *Blood Press*. 2012;21:240-248
22. Tonelli M, Wiebe N, Fortin M, Guthrie B, Hemmelgarn BR, James MT, et al. Methods for identifying 30 chronic conditions: Application to administrative data. *BMC Med Inform Decis Mak*. 2015;15:31
23. Roos LL, Gupta S, Soodeen RA, Jebamani L. Data quality in an information-rich environment: Canada as an example. *Can J Aging*. 2005;24 Suppl 1:153-170
24. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. *Stroke; a journal of cerebral circulation*. 2005;36:1776-1781
25. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in icd-9-cm and icd-10 administrative data. *Med Care*. 2005;43:1130-1139
- [Dataset] 26. Garrison SR, Kelmer MD, Korownyk T, Kolber MR, Allan GM, Bakal JA, Singer AG, Katz A, McAlister FA, Padwal RS, Lewanczuk R, Hill MD, McGrail K, O'Neill BG, Greiver M, Manca DP, Mangin DA, Wong ST, Kirkwood JEM, McCormack JP, Yeung JMS, Green LA. Data from: Tolerability of bedtime diuretics: A prospective cohort analysis *Pragmatic Trials Collaborative Website*. April 30, 2023. <https://www.PragmaticTrials.ca/>
27. Johnson TM, 2nd, Sattin RW, Parmelee P, Fultz NH, Ouslander JG. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. *J Am Geriatr Soc*. 2005;53:1011-1016
28. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the uk (time study): A prospective, randomised, open-label, blinded-endpoint clinical trial. *Lancet*. 2022;400:1417-1425
29. Perry LA, Surowiec S M, Danso DA, Kerobo OI, Anugwom AA, Couvertier KP. Evaluation of administration time and adherence rates of morning vs. Bedtime dosing of

1
2
3 antihypertensive medications. *Journal of Contemporary Pharmacy Practice*. 2019;66:11-
4 16

- 5
6 30. Garrison SR. Bedmed-frail: Does the potential benefit of bedtime antihypertensive
7 prescribing extend to frail populations? *National Institutes of Health Clinical Trials*
8 *Registry* <https://www.clinicaltrials.gov/ct2/show/NCT04054648/> Accessed March 16
9 2023
10

11
12
13
14
15 **FIGURE LEGENDS**

16
17
18 Figure 1:

19
20 Figure 1 Study flow diagram for analysis of adherence
21
22

23
24
25 Figure 2:

26
27 Figure 2 Medication frequency at baseline. HCTZ = hydrochlorothiazide
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Study flow diagram for analysis of adherence

163x190mm (150 x 150 DPI)




Figure 2 Medication frequency at baseline. HCTZ = hydrochlorothiazide

154x200mm (150 x 150 DPI)

Tolerability of Bedtime Diuretics: A Prospective Cohort Analysis (Supplemental Information)

Supplemental Table 1. Comparison of baseline characteristics for participants that were excluded vs. included in the primary outcome analysis			
Characteristics	Excluded (n=46) No. (%)	Included (n=533) No. (%)	p-value
Sex, female	27 (58.7)	308 (57.8)	0.99
Province			
Alberta	39 (84.8)	442 (82.9)	0.84
British Columbia	4 (8.7)	48 (9.0)	0.99
Manitoba	2 (4.4)	35 (6.6)	0.76
Saskatchewan	1 (2.2)	8 (1.5)	0.53
Rural resident	4 (8.7)	71 (13.3)	0.49
Age, mean (STD), y	64.6 (10.6)	65.5 (10.0)	0.55
≤ 29	0	1 (0.2)	0.99
30 - 39	0	2 (0.4)	0.99
40 - 49	3 (6.5)	24 (4.5)	0.46
50 - 59	9 (19.6)	116 (21.8)	0.85
60 - 69	18 (39.1)	202 (37.9)	0.87
70 - 79	11 (23.9)	146 (27.4)	0.73
80 - 89	5 (10.9)	39 (7.3)	0.38
≥ 90	0	3 (0.6)	0.99
Ethnicity			
White	43 (93.5)	504 (94.6)	0.73
South east asian	0	12 (2.3)	0.61
Asian	1 (2.2)	3 (0.6)	0.28
First nation	0	6 (1.1)	0.99
Black	0	0	0.99
Other	1 (2.2)	7 (1.3)	0.49
Decline to answer	1 (2.2)	1 (0.2)	0.15

Education level			
Less than high school	4 (8.7)	21 (3.9)	0.13
High school diploma	19 (41.3)	147 (27.6)	0.06
Technical or trade college diploma	9 (19.6)	146 (27.4)	0.30
University degree	13 (28.3)	219 (41.1)	0.12
Decline to answer	1 (2.2)	0	0.08
Annual household income, CAD\$			
< 25,000	4 (8.7)	25 (4.7)	0.28
25,000 to 100,000	20 (43.5)	287 (53.8)	0.22
> 100,000	20 (43.5)	189 (35.5)	0.34
Decline to answer	2 (4.4)	32 (6.0)	0.99
Comorbidities ^a			
Coronary artery disease	9 (19.6)	100 (18.8)	0.85
Diabetes	6 (13)	92 (17.3)	0.54
Sleep apnea	11 (23.9)	99 (18.6)	0.43
Chronic kidney disease	7 (15.2)	48 (9.0)	0.19
COPD	6 (13.0)	50 (9.4)	0.43
Stroke	1 (2.2)	28 (5.3)	0.72
Heart failure	0	10 (1.9)	0.99
Hip fracture	1 (2.2)	2 (0.4)	0.22
Cigarette smoker (current)	2 (4.4)	42 (7.9)	0.56
Nocturia, median (IQR), nocturnal urinations/wk	7 (0-14.0)	6 (1-10.5)	0.61
Does not experience nocturia	12 (26.1)	129 (24.2)	0.72
Nocturia occurs but "not a problem"	21 (45.6)	255 (47.8)	0.88
Nocturia "a minor problem"	12 (26.1)	139 (26.1)	0.99
Nocturia "a major problem"	1 (2.2)	10 (1.9)	0.60
Physical exercise, median (IQR), days per week ^b	3 (0-5.0)	3 (0.5-5.0)	0.42
0	15 (32.6)	133 (25.0)	0.29
1	6 (13.0)	43 (8.1)	0.26
2	1 (2.2)	68 (12.8)	0.03
3	6 (13.0)	75 (14.1)	0.99
4	6 (13.0)	54 (10.1)	0.46
5	2 (4.4)	49 (9.2)	0.41

6	1 (2.2)	15 (2.8)	0.99
7	9 (19.6)	96 (18.0)	0.84
BMI, median (IQR), Kg/M ²	27.7 (26.1-33.4)	28.3 (25.5-32.3)	0.80
Underweight (< 18.5)	0	3 (0.6)	0.99
Normal weight (18.5 - 24.9)	9 (19.6)	105 (19.7)	0.99
Overweight (25 - 29.9)	21 (45.7)	220 (41.3)	0.64
Obese (≥ 30)	16 (34.8)	205 (38.5)	0.75
EQ-5D-5L overall health score, median (IQR) ^c	80 (75-90)	80 (75-90)	0.88
Physically frail ^d	7 (15.2)	73 (13.7)	0.82
Cognition ^e			
Normal	41 (89.1)	496 (93.1)	0.37
Questionable impairment	3 (6.5)	36 (6.8)	0.99
Impairment consistent with dementia	2 (4.4)	1 (0.2)	0.02


^a Derived from Alberta provincial health claims data and self-report.

^b "How many days in the past week have you exercised for 30 minutes or more, vigorously enough to raise your breathing rate?"

^c Self-rating of overall health on a scale of 0 (worst) to 100 (best).

^d As per Tilburg Frailty Indicator's physical sub-scale (sub-scale score ≥3 defines physically frail).

^e As per Short Blessed screening test score. Considered to be normal (0-4), questionable impairment (5-9), or impairment consistent with dementia (>9).



Supplemental Figure 1. 6-week change in overnight urinations per week.

Figure is the change in the number of overnight urinations per week experienced by hypertensive primary care patients 6-weeks after being randomly allocated to switch their only blood pressure lowering pill from morning to bedtime. Grouped by those whose pill contained a diuretic (90.7% of which were thiazides), and those who used a different class of blood pressure lowering medication.

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6-13
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	9-11
Bias	9	Describe any efforts to address potential sources of bias	12-13
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	11-13
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	11-13
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	14-18
Outcome data	15*	Report numbers of outcome events or summary measures over time	16-18

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-18
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14, 17-18
10				
11				
12	Discussion			
13	Key results	18	Summarise key results with reference to study objectives	19
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19-20
15				
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	20
18				
19				
20	Generalisability	21	Discuss the generalisability (external validity) of the study results	19-20
21				
22	Other information			
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	22
24				
25				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.